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The synthesis of four new ajoene analogues is presented in this thesis. The key to the synthesis was 
gaining access to a phenol derivative containing the ajoene core structure (sulfoxide / vinyl disulfide) 
that could be functionalised with various substituents. Evaluation of biological activity returned excellent 
in vitro activity against a WHCO1 oesophageal cell-line, in which a derivative with a 
methoxycarbonylmethylene substituent (PMB-ester) was shown to be the most active analogue that 
was fifteen times more active than Z-ajoene with an IC50 of 1.7 M. An aqueous solubility assay reveals 
that aqueous solubility increased with subsituition and the analogues with amido or acetate substituents 
were the most soluble ones. The analogues were also shown to enhance the apoptotic effects of two 
chemotherapeutic drugs Doxorubicin and Vincristine via chemosensitization. This effect was attributed 
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A375   Human malignant melanoma epithelial cell-line 
ACCN    1,1’ –Azobis(cyclohexane-1-carbonitrile) 
ADP   Adenosine diphosphate 
AML   Acute myeloid leukemia 
ATM   Ataxia-telangiectasia mutated 
BCC   Basal cell carcinoma  
BF3: Et2O  Boron trifluoride etherate 
BHK21   Baby hamster kidney cells 
BJA-B   Burkitt lymphoid cells 
brs   broad singlet 
Ca2+   Calcium 
CDK   Cyclin dependant kinase 
d   doublet 
dd   doublet of doublets 
ddd   doublet of doublet of doublets 
dt   doublet of triplets 
DATS   Diallyl trisulfide 
DCM   Dichloromethane 
DMAP   Dimethylaminopyridine 
DMEM   Dulbecco’s modified Eagle Medium 
DMF   Dimethyl formamide 
DMSO   Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid  












ER   Endoplasmic reticulum 
ERK   Extra-cellular signal related kinases 
Et   Etoposide 
EtOAc   Ethyl acetate 
FasL   Fas-lagand  
FBS   Fetal bovine serum 
FS4   Human fibroblast cells 
GR   Glutathione reductase 
HCl   Hydrochloric acid 
HL60   Human leukemic cells 
HRMS   High resolution mass spectroscopy  
HSAB   Hard-soft acid-base theory 
HSQC   Heteronuclear Single Quantum Coherence 
Hz   Hertz 
IIDMM   Institute of Infectious Diseases and Molecular Medicine 
i.p.   Intraperitoneal injection 
JNK   Jun N-terminal kinases 
KB   Nasopharyngeal carcinoma 
KIP1   Kinase inhibitor protein 1 
LAH   Lithium Aluminium hydride 
m-CPBA  meta-Chloroperbenzoic acid 
MMP   Mitochondrial membrane permeabilization 
Mp   Melting point 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAC   N-acetylcysteine 












NMR    Nuclear Magnetic Resonance 
NECSA  South African Nuclear Energy Corporation   
NEt3   Triethylamine 
OCS’s   Organosulfur compounds 
PARP   Poly (ADP-ribose) 
PBMC   Peripheral blood mononuclear cells 
PBS   Phosphate-buffered saline 
PEG400  Polyethylene glycol 400 
PET   Positron emission tomography 
PT   Proton transfer 
PtK2   Marsupial kidney cell 
pRb   Retinoblastoma protein 
s    singlet 
SAR   Structure-activity relationship 
RBC   Red blood cells 
Rf   Retention factor  
ROS   Reactive oxygenated species 
t   triplet 
TBDPS  tert-Butyldiphenylsilyl ether  
THF   Tetrahydrofuran 
THP   Tetrahydropyranyl 
TLC   Thin later chromatography  
TNF   Tumor necrosis factor 
TR   Trypanosoma cruzi trypanothione reductase 
UCT   University of Cape Town 












WHCO1  Oesophageal epithelial cancer cell-line 
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Chapter 1: Review of Biological and Synthetic aspects of Ajoene 
 
1.1 Introduction  
 
This thesis describes the synthesis of several novel ajoene analogues designed for elucidating the 
biological mechanism of ajoene-induced anti-cancer activity. The project spans across a few 
disciplines, thus this chapter will offer an overview of the fundamental concepts and background 
information relevant to the project.  
1.2 Overview of Garlic  
 
The current human civilization has benefited tremendously from ancient ones who showed the 
importance of using plants to combat various infections and inflammations.1,2 Plants such as Garlic or 
Allium sativum (thought to be of Central Asian origin) have been documented since around 2600-2100 
BC to possess therapeutic benefits, although at that stage the exact cause of the benefits weren’t 
known.3, 7 The therapeutic benefits were later attributed to potent organosulfur compounds(OCS’s), 
which are notably three times higher in garlic than in any other species of the same class .4     
1.2.1 Organosulfur Compounds Found in Garlic  
The two types of OCS’s that are predominately located in whole garlic cloves are γ-glutamylcysteines 
and cysteine sulfoxide,5, 6 Allylcysteine sulfoxide (alliin) is a major constituent, which upon maceration of 
the full clove is converted by its enzyme allinase (stored in a separate mesophyll vacuole) into 2-
propenesulfenic acid (see Scheme 1, (i)). The sulfenic acid is unstable and spontaneously condenses 
to form the thiosulfinate Allicin together with other OCS’s (see Scheme 1, step 2).5 Allicin has been 
shown to possess an array of medical benefits, and can be synthesized from diallyl disulfide and 
peracetic acid, the latter from a mixture of hydrogen peroxide and acetic acid (see Scheme 1, (ii)). 
Allicin is also unstable and rearranges to more stable products.4, 5 Some of the main products found in 













Scheme 1: (i) step 1: Conversion of alliin to 2-propenesulfenic acid and 2-aminoacrylic acid, step 2: 
self-condensation of 2-propenesulfenic acid into Allicin, (ii) The synthetic route to allicin from diallyl 
disulfide.   
 
Figure 1: Examples of OSC’s found in garlic. 
1.3 Ajoene 
 
Ajoene (E/Z-4,5,9-trithiadodeca-1,6,11-triene-9-oxide) was first characterized by Block and Apitz-Castro 
in the 1980s as a stable product of allicin self-condensation. They postulated that two allicin molecules 












vinylthionium ion. Lastly, the 2-propenesulfenic acid adds via a Michael-type addition (to the 
vinylthionium) resulting in the (E/Z)-ajoene (see Scheme 2).8 
 
Scheme 2: Rearrangement of allicin to (E/Z)-ajoene.   
The allicin rearrangement products shown in Figure 1 above share common structural functionality 
such as disulfide and in some examples trisulfides, in which the disulfide is thought to be the 
pharmacophore responsible for the various biological activities. Ajoene is noticeably different from the 
other molecules as it has a vinyl disulfide group, which is thought to increase the reactivity of the 
disulfide bond, thus making it more active than any of the related compounds. Since its discovery, anti-
thrombotic activity, 8 as well as other biological activities ranging from anti-microbial9, anti-obesity10, 
anti-fungal11 and also anti-cancer12 have been identified, the latter being the most relevant to the 
current study.   
1.4 Cancer 
   
Cancer is described as a class of disease that is characterised by the uncontrolled growth of abnormal 
cells that are capable of spreading to other cells in the vicinity and organs (via metastasis). The survival 
of abnormal cells is governed by their ability to elude apoptosis. Cancer is a global burden that 
accounted for 8 million deaths in 2008. Furthermore, 70% of deaths occur in low- and medium-income 
parts of the world.13 
1.4.1 Treatment of cancer  
Since cancerous cells survive by avoiding apoptosis, most of the therapeutic drugs available have been 
designed to restrict the rapidly-growing cells by inducing programmed cell-death. Chemotherapeutic 
drugs that are toxic to other healthy cells are referred to as cytotoxic, and a number of 
chemotherapeutic drug classes are available on the market grouped by their mode of action as 












Chemotherapeutic drug groups:14 
1. Alkylating agents: they have the ability to impair cell functionality by forming covalent bonds with 
nucleophilic groups such as carbonyl, sulfhydryl, amino and phosphate found in the cancer cells. DNA, 
RNA and proteins are targets for alkylating agents such as platinum complexes.  
2. Anti-metabolites: they mimic the naturally occurring building blocks of DNA and RNA synthesis, 
where they will compete with the natural substrate for synthesis thus halting normal processes. 
Fludarabine is one such example of the purine analogue. 
3. Natural products: Vinca alkaloids are derived from the periwinkle plant Vinca rosea, are able to bind 
to tubilin and prevent polymerization of microtubules that are required during cell division. Taxanes that 
are derived from yew plant extracts promote and stabilise the assembly of microtubules, blocking the 
cell-cycle at mitosis. Docetaxal and Paclitaxel are good promoters of microtubule assembly and 
apoptosis. 
4. Anthracyclines: they are products originating from the fungus Streptomyces percetus var caesius, 
and intercalate between DNA bases as well as inhibit DNA topoisomerases I and II. Doxorubicin is one 
such example from Streptomyces.      
There are many side-effects associated with the above drugs such as nausea, diarrhea, bone marrow 
depression and also skin changes. Over time the cancer cells develop resistance to the drugs, and 
such challenges have led to development of better chemotherapeutic agents with fewer side-effects. 
1.4.2 The Eukaryotic cell-cycle 
There is always a need for continuous cell proliferation in eukaryotes. In mammals, such processes are 
required for both the mainte ance of tissues and the organs that are needed to sustain life. The cell-
cycle is a highly regulated sequence of events leading to cell division and multiplication.15, 16 All the 
classes of anti-cancer drugs described target various sites within the cycle, and with this knowledge of 
the cell-cycle designing more robust drugs can be achieved. 
The cell-cycle (see Figure 2) comprises 5 phases: 
i) A large proportion of cells in human bodies are in out-of-cycle state quiescent (G0). 
ii) Protein synthesis and initial cell growth occurs at G1. 












iv) Secondary growth and microtubule formation occurs at the G2 phase. 
v) Mitosis cell-division into identical daughter cells, (M) phase. 
Cell proliferation is promoted by cyclin dependant kinase (CDK) family of serine/threonine kinase in 
complexation with their regulatory cyclin partners.15 
 
 
Figure 2: Cell-cycle portraying the critical regulators and checkpoints. The cycle comprise of G1, S, G2 and M as 
indicated with checkpoints in G1, G2, and M phases as shown by horizontal green T-bars. Sequential activation of 
the Cyclin-CDK complexes drives the cell cycle (red arrows). The cell-cycle progression can be blocked by 
negative regulators such as p16, (retinoblastoma protein) pRb, P27/ KIP1 (kinase inhibitor protein 1) or by exit 
from the cell cycle into G0 phase. Growth-stimulatory signals can lead to re-entry into the cell cycle.16  
Cyclin D-CDK4/6 is required for initiation of the cell-cycle from the G0 state and it acts on pRb by 
causing hypophosporylation, which in its active state halts cell-cycle by binding and repressing 
transcription factor E2F. Whereupon, dissociation of pRb from E2F leads to transcription of genes 
required to proceed to the S phase. The cyclin E-CDK2 active complex drives progression to the S 
phase through the restriction point, the S phase being the most important as DNA synthesis is initiated 
by cyclin A-CDK2. Upon completion of DNA synthesis, cyclin B-CDK1 is activated which leads to entry 
into the M phase at which two new daughter cells are formed by mitosis. At this point the cell newly 
formed cells may re-enter into another cycle or go in out-of-cycle state.15-17 Progression through the 
various cell cycle phases and transitions is strictly monitored by sensor mechanisms, called 
checkpoints (restriction points), which maintain order of events. Any defect detected will trigger 












1.4.3 Apoptosis  
As cells are continuously proliferating to maintain a balance in the mammalian development, apoptosis 
has been adopted to be the mode by which cell density is kept in check. This occurs as a normal 
physiological response to the various imbalances experienced, which may include irreparable DNA 
damage. Apoptosis is a process by which old, damaged or dangerous cells are disposed off efficiently. 
It is also described as an active, energy-demanding, genetically determined process, proceeding 
without resulting in any inflammation as opposed to necrosis. Necrosis is an involuntary, energy-
independent cell death that affects a group of cells resulting in inflammation.16 
Apoptosis is tightly regulated by several molecular pathways, some of which have been well-defined. 
Damage sensors such as ATM (“ataxia-telangiectasia mutated”) located in the nucleus or on death 
receptors on the cell membrane, are capable of initiating signalling cascades that lead to an ‘execution 
machinery’ resulting in cell death. Two prime pathways utilized are mitochondrial (intrinsic) and death 
receptor-mediated (extrinsic) apoptosis. The two pathways are intimately linked by a series of caspases 
such as cysteine proteases (see Figure 3). 16, 18 
 
Figure 3: Cellular apoptosis pathways. The two pathways converge into a single point at caspase 3 
irrespective of the stimuli initiating either pathway.  
The extrinsic pathway is governed by an exterior stimulus, such as growth factor withdrawal matrix 
detachment and cytokine-mediated killing. The pathway is initiated when an appropriate death ligand 
such as tumor necrosis factor (TNF) and Fas-lagand (FasL) interact with its matching receptor (TNF 
and Fas receptor) respectively. These interactions lead to the activation of the caspase cascade, finally 












The intrinsic pathway is initiated by intracellular stimuli such as DNA damage and cellular stress. The 
Bcl-2 family of proteins are responsible for mediating the pathway, and they exist in two opposing 
states, namely: anti- and pro-apoptotic forms. As a response to apoptotic signals such as anti-cancer 
drugs the pro-apoptotic Bcl-2 family of proteins such as BaX translocate to and alter the mitochondrial 
membrane permeability that leads to cytochrome c release and inevitable activation of caspase 
cascade. Anti-apoptotic Bcl-2 family members such as Bcl-2 and Bcl-xL can counter the effects caused 
by the stimuli. 16, 18  
1.4.4 Other Causes of Apoptosis 
The endoplasmic reticulum (ER) plays a major role in the proliferation of eukaryotic cells as it provides 
the environment for proper protein folding and modification. 19 The lumen of the ER is a cellular storage 
compartment for calcium (Ca2+) and is also a redox active site required for protein folding. Disruptions 
such as protein unfolding will lead to an unfolded protein response (UPR), if the cell is incapable of 
restoring normal ER function in which case apoptotic signals such as NF-κB are activated and 
subsequently the dysfunctional cell will be destroyed.  
There are various proposed mechanisms to link how ER stress links to the activation of apoptosis but 
none of them have been clearly described to date. The process may proceed via: activation of 
proteases, transcription factors and Bcl-2- family proteins. Release of Ca2+ from the ER lumen has 
been shown to activate caspase 12 as well as further downstream caspase activation. 19, 20 
1.5 Anti-cancer Activity of Ajoene 
 
1.5.1 Anti-mutagenic 
The first aspect of ajoene’s anti-cancer properties concerns prevention as opposed to treatment. 
Experimental and epidemiological studies conducted have shown that the consumption of garlic has a 
positive impact on people as it lowers risks associated with cancer and other diseases.21, 22 These 
benefits may be attributed to OCS’s found in garlic.  
Ajoene, is more distinctive than the others in that it has been shown to have the ability to inhibit the 
activation of known carcinogenic agents such as 12-O-tetradecanoylphorbol-13-acetate, benzo[a] 
pyrene and 4-nitro-1, 2-phenylenediamine in Salmonella Typhimurium in vitro. 23 The exact mechanism 
that is employed to eliminate the carcinogen is not clearly understood, but it is proposed that it may be 












bioactivation of carcinogens, and also by detoxification via phase II enzymes such as glutathione 
peroxidases.21 
1.5.2 Anti-tumour 
Ajoene’s anti-tumour ability has been documented since the early 1990’s, where it was shown to inhibit 
tumor cell proliferation in a number of cell lines with IC50’s that range from 5-40 M.24-27  This is both in 
vivo and in vitro as described later.  
Ajoene’s ability to inhibit proliferation was first shown by Schrafenberg and co-workers in a letter 
published in 1990. They found that ajoene, in vitro, was cytotoxic towards tumourogenic Burkitt 
lymphoid (BJA-B) cells and caused apoptosis, although the exact mode as to how the apoptotic 
response is activated wasn’t clear at the time. Conversely, the non-tumorgenic cells that are derived 
from baby hamster kidney (BHK21) and human fibroblasts (FS4) cells were not susceptible towards 
ajoene’s cytotoxicity.24 
 Over the years there have been a number of reports on the anti-tumour effects of ajoene that support 
the observation by Scharfenberg. A comprehensive study conducted by Dirsch and co-workers showed 
that ajoene is indeed selective towards tumouorgenic cells as opposed to normal cells. Ajoene induced 
apoptosis in human leukemic (HL60) cells but not in peripheral blood mononuclear cells (PBMC) that 
were isolated from healthy donors.27 Dirsch’s findings were corroborated by Li and co-workers, which 
showed ajoene’s specificity towards tumourogenic cells and not healthy cells. In their study, HL60 cells, 
nasopharyngeal carcinoma (KB) and one normal marsupial kidney cell line (PtK2) were each subjected 
to an increasing concentration of Z-ajoene (1-20 M) and the survival of cells monitored after 48 hours. 
Their results showed what Dirsch and Scharfenberg had proposed about ajoene’s specificity (see 
Figure 4). The HL60 cells were more sensitive to the varying concentration of ajoene in which only 10 
% of cells survived exposure. Nasopharyngeal carcinoma was less sensitive towards ajoene with 30 % 
of cells surviving. Contrary to the two cancer cell lines 75 % of cells in the normal marsupial cells 













Figure 4: The effects of Z-ajoene on cell line cytotoxicity: HL60-●-, KB -■-, and PtK2-Δ-, were exposed 
to increasing concentrations of Z-ajoene (1-20 M) for 48 hours.  
In vivo, ajoene has been shown to inhibit tumourogenic growth in both humans with basal cell 
carcinoma (BCC), a skin cancer type that is prevalent amongst adults that have suppressed immune 
systems, as well as mouse model (xenografts).25, 26, 28, 29 In a study conducted by Tilli and co-workers, 
25 test subjects were each treated with a 4 % ajoene cream onto the tumours. After 6 months of 
treatment 23 of the test subjects displayed a positive response to the treatment, where tumour sizes 
were reduced by about 80 %. Three subjects displayed a negative response as tumours increased and 
1 subject showed no change after treatment, (see Figure 5). 
 












In a mouse model, the mice were innoculated with various tumours at the start of the study and then 
subjected to varying concentrations of ajoene (2, 4 and 8 mg/kg) via intraperitoneal (i.p.) injection every 
day for 4 weeks. After this period it was clear that the administration of ajoene had retarded tumour 
growth in rodents and it was also noted that ajoene inhibits tumor growth by 2-3 fold compared to the 
control cells, (see Figure 6).25, 26  
 
Figure 6: Effects of ajoene administered by i.p. injection on the growth of primary subcutaneous 
B16/BL6 tumor cells over 4 weeks. 
1.5.3 Chemosensitization  
Chemosensitization is a strategy to counteract the resistance of tumour cells towards anticancer 
agents. A chemosensitizing agent should have the ability to reinduce the sensitivity of tumours towards 
chemotherapeutic agents by reversing strategies employed by tumours such as detoxification, and also 
overexpression of pumps that efflux the chemotherapeutic drugs.30 
Ajoene has been shown by Hassan to possess the ability to reinduce sensitivity of drug-resistant acute 
myeloid leukemia (AML) cells towards fludarabine and cytarabine.12b It was shown that ajoene inhibits 
the activation of anti-apoptotic Bcl-2 proteins which activate caspase-3 resulting in an apoptotic 
response.27 A combination of the two drugs and ajoene displays a decrease in bcl-2 expression and an 
increase in caspase-3 activation, while ajoene did not cause any apoptotic response on its own against 
the AML cells. Thus it can be said that it was indeed a chemosensitization effect that was displayed by 













1.6 Signaling pathways 
 
As mentioned previously there are two pathways to induce apoptosis in cells either via the mitochondria 
and caspase cascade or via surface death receptors.16 Dirsch showed that treatment of HL-60 with 
increasing concentrations of ajoene caused a dose-dependent and time-dependent release of reactive 
oxygenated species (ROS), which was predominately composed of hydrogen peroxide. The production 
of ROS leads to the activation of transcription factor NF-κB, which is also known to be activated upon 
oxidative stress with the net result being apoptosis of the cell.27, 31 To prove their hypothesis that ROS 
acts as the signal for apoptosis they incubated an antioxidant N-acetylcysteine (NAC) with ajoene in the 
HL-60 cells and found that it reduced the release of ROS, as well as both apoptotic activity and the 
activation of the NF-κB. Upon activation of NF-κB, it is thought that other pathways are activated which 
lead to apoptosis where the caspase cascade is not involved, and thus ROS is upstream of the 
mitochondrial-dependent activation.27 
Ajoene-induced cell death is a time-dependent process in which activities was observed as early as 5 
hours of incubating the HL-60 cells with ajoene. An experiment was set up to test whether caspase 
activation occurred upon ajoene treatment by utilizing a fluorometric DEVD-cleavage assay. It was 
noted that caspase-3 like activity was detected at about 4 hours and that increased extensively after 8 
hours of the experiment. This result was confirmed by the cleavage of PARP [poly (ADP-ribose) 
polymerase – a 116-kDa nuclear protein involved in DNA repair] into a fragment which is 85-kDa in a 
time-dependent manner (see Figure 7a). Interestingly, it was also shown that CD95 death receptors 
were not activated upon ajoene treatment, which is evidence that apoptosis proceeds without their 
involvement. Moreover, cells that were treated with the caspase inhibitor zVAD-fmk and ajoene, 
showed no fragmentation of the DNA material implying that caspase activation is indeed responsible for 
















                            (a)                                                           (b)   
Figure 7: (a) Time-dependent cleavage of PARP upon caspase-3 activation, (b) DNA content treated 
with zVAD-fmk and ajoene to display caspase activation. 
Another important signaling pathway was also proposed by Dirsch, in which ajoene promoted 
mitochondrial membrane permeabilization (MMP). This is known to be a vital component in cell death 
(see Figure 8a). The activation of caspase-3 is linked to the release of cytochrome c into the cytosol in 
HL-60 cells. Significant cytochrome c was detected within the cytosol after 4 hours of the cells being 
exposed to ajoene (20 M), which again also displayed the time-dependency of ajoene exposure to 
cell-death response and that release of cytochrome c precedes caspase activation. Cytochrome c binds 
to the cytoplasmic protein Apaf-1 initiating the caspase cascade, which results in a loss of 
transmembrane potential (ΔΨm) that was confirmed by confocal microscopy (see Figure 8b). The 
mechanism mentioned here does not require JNK (Jun N-terminal Kinases), but is amplified by the 
inhibition of ERK (extra-cellular signal related kinases). 16, 27, 32       
 
Figure 8(a): The upper panel represents a time-course of ajoene-mediated cytochrome c release into 
the cytosol as treated with ajoene (20 M), as positive control with etoposide (Et,17 M) for 5h. The 
lower panel reflects a time-course of cytochrome c accumulation for the indicated time. In parallel, at 
each time-point, cells were preincubated for 1 h with the caspase inhibitor zVAD-fmk (100 M) and then 













Figure 8(b): Dissipation of MMP in cells treated with ajoene (20 M for 8h), stained with the 
fluorochrome JC-1 and analyzed by fluorescence microscopy. The red fluorescence reflects the 
multimer form of JC-1 localized in mitochondria under control (untreated) conditions. The green 
fluorescence corresponds to monomer JC-1 after ajoene-induced dissipation of MMP.27  
As mentioned previously the Bcl-2 family of proteins are able to inhibit apoptosis by preventing the 
release of cytochrome c out of the mitochondria.16 Incubation of HL-60 with Z-ajoene resulted in the 
induction of cleavage of Bcl-2, a 26-kDa protein, into a 23-KDa fragment, which was characteristic as it 
had been previously been obtained upon treatment  of HL-60 cells with etoposide (see Figure 9).33 
From this result it was clear that Bcl-2 was only cleaved upon the activation of caspase-3, as treatment 
with zVAD-fmk didn’t show any cleavage of Bcl-2 and PARP  implying that Bcl-2 is a downstream 
substrate for caspase-3.  
    
Figure 9: Z-ajoene induced Bcl-2 cleavage in HL-60 cells. Cells were treated with Z-ajoene 40 M at 
various times. Etoposide (E) was used as a positive control in the experiment.33     
1.7 Mode of Action of Ajoene 
 
 Ajoene and diallyl trisulfide (DATS) have been shown to exhibit their anti-cancer properties by 
associating with the mitochondrial-mediated apoptotic pathways, which results in G2/M cell-cycle arrest. 
However a comprehensive account of this has not yet been formulated, but a few examples have been 
proposed.34, 35 It has been well established that disulfide bonds in OCS’s have the ability to act as thiol 
oxidizing agents, modifying enzymes and proteins via thiolation of exposed cysteine residues located 












1.7.1 Modification of Microtubule Formation and Cell-Cycle Arrest  
It was proven by Hosono that apoptosis occurs as a result of oxidative modification of tubulin by 
thiolation on cys-12 and cys-354 to result in S-allylmercaptocysteine on each subunit.38 Upon such 
modifications tubulin polymerization and microtubule formation are inhibited. As mentioned earlier that 
microtubule assembly is essential for mitosis, it will clearly be inhibited at this point and thus lead to 
cell-cycle arrest at G2/M phase.16, 25, 38 Other sites in the cells are implicated by induction of cell-cycle 
arrest by OCS’s that leads to an apoptotic response via the mitochondrial-mediated pathways as 
mentioned earlier (see Figure 10). 
 
 Figure 10: Modifications by organosulfur compounds on microtubule leads to apoptosis via a series of 
ordered events.  
1.7.2 Modification of Enzymes   
Gallwitz and co-workers have demonstrated that ajoene is a covalent inhibitor of human glutathione 
reductase (GR) and Trypanosoma cruzi trypanothione reductase (TR), in which both enzymes have 
been shown to react in a time and temperature-dependent manner towards their substrates and also 












two cysteine residues may react with ajoene to form mixed disulfides. Evidence of such an inhibition of 
the enzymes was extrapolated from X-ray crystallography which showed an oxidative modification of 
cysteine-58 on GR, to form a CH2=CH-CH2-SO-CH2-CH=CH=S-SR’ (R’= GR cysteine-58) covalently 
bound to the enzyme (see Scheme 3(i)). Further evidence of the modification was observed by the 
presence of hydrogen-bonding that existed between ajoene’s sulfoxide group and NH- group on 
alanine-34 in the near vicinity. This is thought to have a bearing on ajoene’s activity towards GR 
inhibition. By comparison DATS did not show any inhibitory effects on GR,36 this result implies a 
specificity of GR towards ajoene and particular the Z-isomer. The cysteine-58 nucleophilically attack the 
vinyl-S as opposed to the allyl-S which is a strange outcome as the allyl-S would be expected to be 
more electrophilic than the vinyl-S on electronic grounds. In an attempt to model the regioselectivity 
described, ajoene was reacted with free cysteine in the flask and it was indeed found that this yielded 
allyl-S-S-cysteine as a primary product (see Scheme 3(ii)).37 Interestingly when 2 equivalents of 
cysteine are used in the reaction carried out in a neutral medium it formed two products, as the 
ajocysteine (3-((3-(allylsulfinyl)prop-1-enyl)disulfanyl)-2-aminopropanoic acid) and  S-
allylmercaptocysteine (see Scheme 3(iii)). Such results suggest that a secondary exchange process 
between the primary products may ensue.35         
 
Scheme 3: (i) Ajoene reacting with a cysteine residue on GR and thus inhibiting it;36 (ii) Reaction of 













Gallwitz also demonstrated that ajoene-modified GR shows an elevated oxidase activity, in which 
blocking of cys-58 creates a shift in electron density that is directed to the flavin ring of the FAD co-
factor resulting in an increased reduction of molecular oxygen to produce super-oxide radicals. The 
elevation of oxidative species coupled with their inability to promote reduction of glutathione created an 
unmanageable redox environment, resulting in activation of the mitochondrial caspase cascade. This 
depicts a likely mode of action for ajoene in inhibition of tumour proliferation and is also useful in 
rational anti-cancer drug design.35, 36  
1.8 Summary 
 
Garlic has been used for around 5000 years by ancient civilization to combat diseases. It was only in 
the last century that it was uncovered that the benefits were due to the OCS ’s that are in garlic. The 
OCS’s have been described in detail and it was found that ajoene a stable rearrangement of allicin was 
the potent OCS that can be attributed to a lot of the therapeutic benefits outlined. Ajoene possess an 
array of therapeutic benefits, its anti-cancer properties were of most relevance to the current study and 
some of the benefits have been outlined. Interestingly ajoene has been shown to be a multi-target 
agent with the exact mode of action not clearly understood, however it is postulated that the 






















Chapter 2: Synthesis aspects of Ajoene 
2.1 Overview 
 
The structure of ajoene appeared in the literature in 1984 in a paper published by Block and Apitz-
Castro in which ajoene was prepared using a biomimetic synthesis.41 This chapter serves to outline 
some of the advances made thus far in ajoene synthesis as well as limitations to the biomimetic 
synthesis published by Block.   
2.2 Block’s Biomimetic Synthesis  
 
Block developed a synthetic protocol in the 1980’s for ajoene by mimicking how it is formed in Nature. 
Readily available diallyl disulfide was converted via mono-oxidation by per-acetic acid into allicin, which 
was immediately heated in aqueous acetone to form ajoene. The mechanism of ajoene formation was 
described by Block as a self-condensation of allicin, (see Schem  4),8, 41 involving S-sulfenylation (step 
ii) followed by the elimination of allylsulfenic acid to form a vinylthionium ion as shown. Subsequent 
Michael addition with allylsulfenic acid as a nucleophile affords ajoene as a mixture of E/Z –
stereoisomers.     
 












The biomimetic synthesis, however, has proven not to be a general protocol for synthesizing different 
analogues of ajoenes as it requires the R2 group (see Figure 11 for general ajoene structure) to be an 
allyl group for providing the vinyl disulfide grouping. The R1 in principle could be any grouping, but R2 is 
determined by the vinyl disulfide group as observed from the mechanism and hence can’t be varied 
independently. Another issue with the biomimetic synthesis is that the yield of ajoene is rather low, with 
34 % being the highest reported yield in an E: Z ratio of 4: 1.8, 41 It is known that the Z-isomer is more 
biologically active than the E-isomer, and thus it was crucial to develop a synthesis that provided a 
balance between yield and optimization of geometrical selectivity for the Z-isomer. Thus, a sequence 
was developed for accessing derivatives with variable end groups, which will now be described in 
detail.42   
2.3 Terminally-substituted Ajoene analogues 
 
Modern-day medicinal chemistry has been developed on the basis that a range of structurally related 
molecules can be created and tested to ultimately develop a SAR (structure-activity relationship) profile. 
The UCT (University of Cape Town) synthesis was developed on the basis of retaining the biologically 
active pharmacophore based on the vinyl disulfide and sulfoxide groups while replacing the terminal 
groups with various groups to achieve different analogues. A generalised structure of target ajoene 
analogues is depicted in Figure 11.35  
For consistency in this thesis the ajoene analogues are drawn with the sulfoxide on the left-hand side of 
the molecule and the disulfide on the right as depicted in Figure 11. Thus, the “left-hand side of the 
molecule” denotes the R1 group on the sulfoxide end, while the “right-hand side of the molecule” 
denotes the R2 group on the disulfide end.  
 
Figure 11: General structure of ajoene analogues.42 
2.4 University of Cape Town (UCT) synthesis  
 
A four-step synthetic protocol was developed at UCT to access terminally-substituted ajoene 
analogues, since the biomimetic synthesis only works with R2 as an allyl group as already discussed. 
As the key step, the UCT strategy uses a moderately Z-stereoselective radical addition to generate the 













Scheme 5: Synthesis of doubly-end substituted ajoene analogues. 
2.4.1 Step 1 - Propargylation  
The first step starts with a thiol that is obtained commercially or via reaction of R1X (X= halogen) with 
thiourea (see Scheme 6, step (i)) to form an isothiouronium salt. When subjected to potassium 
hydroxide hydrolysis, the latter forms a thiol, potassium halide and urea. In view of the pungent nature 
of thiols, it was more convenient to propargylate in situ. This was achieved by direct addition of 
propargyl bromide following the liberation of thiol from hydrolysis to form the desired propargyl thioether 
1.  
 
Scheme 6: (i) in situ preparation of thiol R1SH; (ii) Propargylation of thiol. 
2.4.2 Step 2 - Radical Addition   
The second step involves the regioselective radical addition of thiolacetic acid to the terminus of the 
alkyne of 1 to form a vinyl thioacetate using ACCN (1,1`-azobis(cyclohexane-1-carbonitrile)) as radical 
initiator. The radical addition was the key step in the synthesis as it was at this point that the Z/E 












was developed by Kampmeier and colleagues in the 1960’s involving regioselective radical addition of 
thiolacetic acid to 1-hexyne at its terminal position to afford the corresponding vinyl thioacetate. The 
reaction follows the classical initiation, propagation and termination sequence that is known in radical 
additions, (see Scheme 7).44 
Upon heating to around 85 °C, the radical initiator ACCN undergoes thermal cleavage to yield an active 
α-cyano radical and nitrogen gas. The α-cyano radical then abstracts a hydrogen from thiolacetic acid 
to generate a thiyl radical, which adds regioselectively to the terminus of the propargyl thioether 1 on 
both steric as well as electronic control, the latter based on formation of the more stable radical 
intermediate. The newly formed radical abstracts a hydrogen on the thiolacetic acid to form a vinyl 
thioacetate, regenerating a new thiyl radical. The reaction is terminated by the dimerization of two thiyl 
radicals to form a disulfide diacetate. The Z-vinyl thioacetate radical provides easier access for the 
abstraction of the hydrogen in the second propagation step, and thus, the Z-product is kinetically 
favoured over the E-product.   
 












2.4.3 Sulfenylating Agent 
The right-hand side of the molecule is constructed from an S-tosyl sulfenylating agent derived itself 
from an appropriate R2-halide.  The thiosulfonate group, -S(SO2)R, is analogous to the O-sulfonate 
ester (i.e. tosylate) that is used in SN2 reactions, except that the thiosulfonate sulphur provides an 
electrophilic site for attack by soft nucleophiles, in contrast to the tosylate which makes the adjacent 
carbon electrophilic. The thiosulfonates are formed via nucleophilic substitution of an R2-halide with 
potassium-thiotosylate, (see Scheme 8 (i)). However, it is important to use the appropriate equivalents 
of salt as further substitutions on the product are possible with an excess, (see Scheme 8 (ii)).    
 
Scheme 8: Synthesis of the sulfenylating agent. 
2.4.4 S-Sulfenylation Step 
Hard-soft acid-base (HSAB) theory was applied in the design of this reaction. The vinyl thioacetate is 
subjected to deprotection by potassium hydroxide in methanol to form an enethiolate, analogous to an 
enolate except with S instead of O. This reaction has to be carried out at -40°C in order to retard the 
geometric isomerisation from the Z-isomer to the more stable E-isomer via a protonation, tautomerism 
(to the thioaldehyde), conformational switch, and re-deprotonation sequence. For addition of the 
sulfenylating agent the reaction is cooled to -78°C, whereupon the enethiolate rapidly displaces the 
sulfonate leaving group to form the desired disulfide via a soft-soft interaction between the two divalent 
sulfurs, (see Scheme 9). 
 












2.4.5 Step 4 - Oxidation 
The final step of the synthesis involves the chemoselective oxidation of the more nucleophilic sulfide of 
the vinyl disulfide / sulfide by limiting the m-CPBA (meta-chloroperbenzoic acid)  oxidant to 1.1 
equivalents as well as maintaining the reaction temperature below -60°C, (see Scheme 10). These 
conditions favour mono-oxidation to occur, on the sulfide sulfur. 
 
Scheme 10: Oxidation of the substituted-ajoene.  
2.5 Summary 
 
The synthetic route developed at UCT can be employed to synthesise a range of terminally-substituted 
ajoene analogues, although it was found that it could not be used to synthesise  ajoene itself, which 
was explained by postulating that the vinyl radical cyclises onto the left-hand allyl group via a 5-exo or 
6-endo-trig process, but this was not investigated further.42 Han’s group at Seoul National University 
have recently managed to synthesise the parent ajoene using the UCT method, but did not give a 
detailed account of their modified synthesis.44  
Ajoene and its analogues are relatively stable to chromatography, and in cases where small R groups 
are used on the termini the E/Z- isomers can be separated, whereas large substituents, such as benzyl 
generally result in inseparable isomers. In the next section, SAR studies will be described. 
2.6 Ajoene Analogues with Improved Water Solubility 
 
2.6.1 Overview 
A library of ajoene analogues were synthesized within our group and tested for their anti-proliferation 
activity on various cancer lines. We were particularly interested in an oesophageal cancer cell-line 
called WHCO1. Results of the SAR study are summarised in Table 1, where replacement of R1 and R2 
were varied independently. Ajoene derivatives were tested either as separate isomers or as a mixture 
of isomers depending on the R group used. Anti-proliferation of the WHCO1 cell-line was determined 
by an MTT assay, which is a colourimetric assay in which live cells appear as purple due to intact 












Initially, the R1 substituents (4a- 4g) were varied and it was identified that having an electron-releasing 
end-group with high lipophilicity provided an increased anti-proliferation activity, with p-methoxybenzyl 
as the most active substituent on R1. The R2 substituent was also optimised (4j-5) and it was found that 
p-methoxybenzyl also gave the best anti-proliferation of WHCO1 cells. Interestingly, having a p-
fluorobenzyl substituent gave a significantly less active analogue suggesting that having electron-
withdrawing groups on the terminus reduces the activity of the central pharmacophore. In cases where 
separation of isomers was possible it was found that the Z-isomer was slightly more active than the E-
isomer by around 30%.42 Hence, replacing both R1 and R2 by p-methoxybenzyl was identified as our 
most active analogue (see Figure 12), which resulted in an inseparable mixture that showed a 
twelvefold increase in activity (2.1 M) relative to Z-ajoene (25 M). The IC50 of this analogue is lower 
than that of the in vitro clinical range for the other chemotherapeutics, cisplatin (9.2 M) and 5-
fluororacil (7.9 M) on the same cell-line.35  
 
Figure 12: Advanced lead 5 identified in an SAR study. 
Advanced lead 5 was tested for its ability to inhibit tumour growth in a nude-mouse model. However, 
owing to its lipophilic nature it was not possible to give oral doses and so it was decided to administer it 
through an intralipid vehicle. The test subjects were each inoculated with 2.50 x 106 WHCO1 cells 
delivered via subcutaneous injection and tumours were allowed to develop over the duration of the 
study.  
At the end of the study it was found that there was no significant effect on tumour growth in the subjects 
that received drug treatment compared to the control subjects, and also that the drug had no negative 
effects on the health of the subjects. Advanced lead 5 that returned very good in vitro activity, was thus 
ineffective in reducing tumour sizes in an in vivo study. This may have been due to its lipophilic nature 
resulting in poor drug bio-availability, but it might also have been due to the drug degrading upon 
administration and thus not reaching the tumours. The latter possibility was further explored when 
advanced lead 5 was incubated in whole blood for two hours at 37°C and it was found that even after 
15 minutes the compound could not be detected by HPLC (see, Figure 13). It may also be postulated 


























Figure 13: Metabolic stability of advanced lead 5, as measured by HPLC. 
The current project was aimed at addressing the first of these issues by introducing groups at the para-
position of the benzyl substituents of 5 that would promote water-solubility. The new target should 
resemble analogue 5 as closely as possible in order to maximize activity and thus the proposed 
modified target was conceptualised as depicted in Figure 14. The next section serves to describe in 
detail the synthesis of ajoenes with substituents that promote an increased degree of aqueous 
solubility, their characterisation and also their biological evaluation. 
 
Figure 14: Illustration of the target water-soluble ajoene, 6 and 6’. 
A second objective was to design the synthesis such that it is possible to place a radioactive 14C-tag on 
one of the p-methoxy methyl groups in an attempt to track the movement and accumulation in nude 
mice xenografts using positron emission tomography (PET). In this case, the radiolabed ajoene 
analogue would still need to resemble 5 as depicted in Figure 15. This was done in collaboration with 
NTeMBI/ NECSA at the nuclear facilities at Pelindaba in South Africa  
 
Figure 15: Illustration of targeted labelled analogue, 7. 
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The UCT synthesis was employed to access the two target molecules and so it was decided to start the 
sequence by synthesis of an advanced intermediate that would allow placement of a radiolabeled tag 
and also a water-soluble group as the last step based on the availability of the tag. This required one of 
the aromatic groups to be a free phenol. 
The synthesis began with attempts to synthesize ajoene 6’ with a free phenol on the left-hand side of 
the molecule. A retrosynthetic analysis based on the UCT synthesis is shown in Scheme 11, which 
indentified synthons 8 and 9 as accessible from methyl p-hydroxybenzoate 12 and p-methoxybenzyl 
chloride 11 respectively. Reagent 9 had previously been synthesized within our group from the chloride 
11.    
 

















Chapter 3: Results and Discussions 
3.1 Studies towards synthesis of Ajoene 6’ 
 
It was envisioned that synthon 8 could be synthesised from thiopropargylated phenol 10, which in turn 
could be accessed via the commercially available phenolic ester 12, (see Scheme 12).  
 
Scheme 12: (i) LiAlH4 (LAH) / THF; (ii) SOCl2/ CHCl3; (iii) Thiourea/ Δ; KOH/ propargyl bromide 
The first step began with an attempt to reduce commercially available methyl p-hydroxybenzoate 12 
with 2 mol equivalents of LAH (Lithium aluminium hydride) to the corresponding benzylic alcohol 13. 
The reaction turned out to be problematic and failed to produce an appreciable conversion as there was 
no formation of a polar spot upon TLC monitoring. Increasing the equivalents of LAH to 4 compared to 
the ester with heating also failed to improve conversion. This result was rationalised by assuming 
formation of the phenoxide in situ via deprotonation by the basic LAH resulting in the reduction in the 
electrophilicity of the ester carbonyl carbon via resonance delocalisation, (see Scheme 13). A degree of 
literature precedence exists on this problem.45  
 
Scheme 13: Resonance delocalisation in the phenoxide ion of 12.  
The desired 4-hydroxybenzyl alcohol 13 was indeed commercially available which was adopted as the 
starting material. However attempts to convert the benzylic hydroxyl group into a better leaving group 
(Cl) using thionyl chloride in chloroform failed to give satisfactory results based on NMR data of the 












converted to a p-quinone methide with evolution of HCl (hydrochloric acid) gas as shown in Scheme 14. 
A similar result has been reported in the literature.45, 48 
 
Scheme 14: Elimination of the target intermediate to form p-quinone methide. 
At this point it was decided to attempt exploiting the SN1 character of the benzylic position for direct 
substitution with a sulfur nucleophile. Thus, benzyl alcohol 13 was subjected to a classical SN1 
substitution using boron trifluoride etherate (BF3: Et2O) and thiolacetic acid in DCM. The reaction was 
expected to proceed via a p-quinone methide (as an attractive Michael acceptor) as shown in Scheme 
15. The reaction involved addition of BF3: Et2O to benzyl alcohol 13 at 0°C, as the Lewis acid was very 
reactive. Reaction was allowed to progress for 30 minutes to facilitate formation of the p-quinone 
methide before adding thiolacetic acid dropwise to the mixture. The reaction was monitored by TLC, 
following the disappearance of the polar benzyl alcohol, which indicated that it had reached completion 
within the first hour. At this point the reaction was quenched with aq.NaHCO3 (sodium bicarbonate). 
The desired thioacetate 14 was purified by column chromatography in 74% yield as a pungent oil and 
its structure confirmed by 1H and 13C NMR analysis in which 14 was shown to agree with the data.49 
 
Scheme 15: SN1 substitution to thioacetate 14 via a p-quinone methide. 
The next step in the sequence involved hydrolysis of the acetate group of 14, but unexpectedly, a 
prolonged treatment with KOH in EtOH or MeOH was necessary for full conversion of the thioacetate. 












deprotonation of the acidic phenolic hydroxyl group to the phenoxide ion, which retarded the facile 
hydrolysis of the thioacetate via electronic repulsion with the hydroxide ion.  
From the findings described it was clear that using the p-hydroxybenzyl starting material to access the 
vinyl thioacetate 8 was problematic on account of the electronic connection between the p-hydroxyl 
group and the benzylic position. Thus, it was decided to lengthen the tether by one carbon atom in 
order to isolate these two functionalities electronically. Importantly, it was thought that adding an extra 
methylene group would have no drastic effect on the biological activity of the ajoene, since the 
pharmacophore resides within the vinyl disulfide and the sulfoxide.35   
Commercially available methyl p-hydroxyphenylacetate 15 was successfully rapidly reduced with LAH 
in THF (tetrahydrofuran) at 0°C to alcohol 16 in high yield, corroborating our earlier findings about 
communication between the two sites. Thereafter, the primary hydroxyl group of 16 was converted to its 
iodide 17 using iodine and triphenylphosphine. The reaction involves formation of an 
alkoxyphosphonium ion of the more reactive hydroxyl group followed by substitution by iodide ion with 
expulsion of triphenylphosphine oxide. Imidazole was added to neutralise the HI which forms as a bi-
product. The reaction was driven by formation of the triphenylphospine oxide and reached completion 
in an hour and a half as seen on TLC by the disappearance of the alcohol and formation of the less 
polar iodide together with the oxide. The resulting product was purified by chromatography in 90% 
yield, and could now be subjected to substitution t  the propargylic sulfide 18, (see Scheme 16). 
 
Scheme 16: (i) LAH/ THF (85%); (ii) I2, Imidazole, PPh3/ THF (90%); (iii) Thiourea, Δ, CH3CN; (iv) KOH/ 
MeOH, Propargyl bromide.  
Reaction of iodide 17 with thiourea proceeded to the isothiouronium salt with ease according to TLC as 
seen by the formation of a product spot that only migrated in a polar medium such as MeOH in DCM at 
a ratio of 1: 9. However, the propargylation step proved to be problematic, since the salt could not be 
hydrolyzed very readily. Once again, the problem encountered in the sequence may have been due to 
the formation of the phenoxide ion in the presence of the KOH, resulting in deactivation of the 












standard SN2 substitution on the iodide 17 with thioacetate ion followed by base hydrolysis and 
propargylation, or (ii) substitution of 17 with a propargylthioate ion directly. Both sequences failed to 
give satisfactory results overall. The thiol derivative of 16 could be accessed from iodide 17 using 
sequence (i) above, but it could not be propargylated to intermediate 18. As a last resort to prevent the 
phenoxide interference, the phenolic hydroxyl group of iodide 17 was protected with a TBDPS group, 
but this underwent deprotection when KOH or NaOMe in MeOH was used to facilitate the nucleophilic 
substitution at the iodide end.  
It was decided to carry out a model study of other possible phenolic hydroxyl protecting groups, which 
revealed that: (i) the THP (tetrahydropyranyl) ether of 4-tert-butylphenol could be readily prepared but 
was rapidly removed by mild acids, (ii) silyl ethers were also tested and it was found that they were 
sensitive to hydroxide ion needed in the transformation of the isothiouronium salt and, (iii) a benzyl 
ether was not investigated as it requires removal by HX (X=halide) or H2, Pd/C, which would not be 
compatible with vinyl thioacetate 8 later in the sequence.   
 All these results suggested that having a free phenol on the “left-hand side” of the molecule was very 
problematic as a lot of the reactions carried out invoked the usage of base, which created a phenoxide 
ion that ultimately deactivated any further chemistry on other functionality within the molecule. 
3.2 Synthesis of Ajoenes, 6 
 
Bearing in mind the challenges encountered with the previous target 6’ It was decided to switch to 
having the free phenol on the “right-hand side” of the molecule, so the new ajoene target was adopted 
as 6, as depicted in Figure 15.  
 
Figure 15: p-Methoxybenzyl / p-hydroxyphenethyl ajoene, 6.  
Retrosynthetic analysis of target 6, according to the basic synthetic Scheme 17 identified synthons 23 
and 19 which could be accessed from p-methoxybenzyl chloride 11 and the methyl p-














Scheme 17: Retrosynthetic analysis of the target ajoene molecule 6. 
3.2.1 Thiotosylate Sulfenylating Agent, 19 
Our initial studies showed that a free phenol on the left-hand side of the molecule prevented further 
chemistry on other functionalities in the molecule, so it was decided to place the phenol group (for 
conversion to OR) on the disulfide end, making it part of the sulfenylating agent. The sulfenylating 
agent would be accessed by an SN2 substitution reaction between iodide 17 and a thiotosylate group 
without invoking phenoxide generation because of the low basicity of the thiotosylate grouping. It was 
hoped that overall the free phenolic hydroxyl group wouldn’t pose problems as before in order to avoid 
implementing a protection / deprotection sequence. The iodide 17 could be prepared from commercially 
available methyl p-hydroxyphenylacetate 15 via two steps that will be described next. 
3.2.1.1 Alcohol, 1639  
The alcohol 16 was synthesized by suspending LAH (3 mol equivalents) into THF at 0°C and slowly 
adding a solution of the methyl p-hydroxyphenylacetate 15 dissolved into a minimum amount of THF 
(see Scheme 18 (i)). The ester reduction was complete after 2 hours as evidenced by TLC analysis in 
which 16 appeared as a dominant polar spot relative to the ester starting material. 1M HCl was slowly 
added to the reaction mixture to quench the reaction and liberate the alcohol product from the 
aluminium salts formed in the reaction, and the resulting solution was filtered through Celite and the 
solid washed with EtOAc. Following drying of the filtrate, and removal of solvent, the residue 












The product was characterised primarily through 1H and 13C NMR data. The 1H NMR of 16 revealed a 
singlet at 8.0 ppm corresponding to the phenolic OH, a pair of AB doublets at 7.05 ppm (H-3) and 6.74 
ppm (H-2) characteristic for a p-substituted phenyl group, two methylene triplets at 3.69 ppm (H-6) and 
2.71 ppm (H-5) and also a primary hydroxyl signal at 3.53 ppm.   
The 13C spectrum revealed absence of the carbonyl carbon, a downfield resonance at 156.6 ppm 
corresponding to C-1 bonded to oxygen and the other quaternary resonance at 131.1 corresponding to 
C-4. The signals for C-2 and C-3 on the aromatic ring were observed at 116.0 ppm and 130.8 ppm 
respectively, and interestingly C-2 was more deshielded than C-3 due to the shielding effect caused by 
mesomeric donation of the phenol hydroxyl into the phenyl ring (see Figure 16). Resonances at 64.3 
ppm and 39.6 ppm corresponded to the two methylene carbon C-6 and C-5 respectively. All the carbon 
signals were successfully correlated with associated protons by HSQC analysis. 
 
 Scheme 18: (i) LAH/ THF/ 2 hrs/ 0°C; (ii) I2, Imidazole, PPh3/ THF/ 2 hrs/ 0°C  
 
Figure 16: Mesomeric effect on the phenol ring. 
3.2.1.2 Iodide, 1740 
The next step involved the conversion of the primary hydroxyl group to the corresponding iodide. Alkyl 
halides are very useful intermediates for carbon-carbon bond formation via substitutions or radical 
reactions, and iodides are the most reactive of the alkyl halides. There are many methods described in 
the literature to achieve this transformation such as: BF3:Et2O / NaI, P4 / I2, SOCl2-DMF / KI, MgI2 and 
HI. However, these procedures suffer from one or more drawbacks such as low yields, long reaction 
times, drastic reaction conditions and tedious work-up procedures. A simple, mild and high-yielding 
procedure was employed in our transformation using iodine, triphenylphosphine and imidazole as 












The 1H NMR for 17 revealed the diagnostic AB doublets characteristic of p-substituted phenyl groups at 
7.06 ppm and 6.78 ppm, as well as a broad singlet at 4.84 ppm corresponding to the phenol OH, two 
methylene triplet signals at 3.31 ppm and 3.10 ppm corresponding to H-6 and H-5 respectively. The 
iodination was confirmed by the disappearance of the primary hydroxyl signal and an upfield shift of the 
H-6 triplet.  
The 13C NMR spectrum revealed two aromatic signals at 129.8 ppm and 115.6 ppm corresponding to 
C-3 and C-2 respectively, two methylene carbons at 39.5 ppm (C-5) and 6.4 ppm (C-6). The signal for 
C-6 offered further evidence for iodide formation in terms of the electron withdrawing oxygen being 
replaced by a highly shielding iodine. 
3.2.1.3 Phenolic Thiotosylate tether, 19  
In the last step in the synthesis of 19 (see Scheme 19), the desired sulfenylating agent was prepared 
by stirring iodide 17 with potassium thiotosylate (1.2 equivalents) in DMF at room temperature for 2 
hours. At this point, TLC analysis indicated reaction completion by virtue of the formation of a more 
polar product relative to the starting iodide 17, after which the DMF was removed under vacuum. The 
resulting residue was suspended into water and extracted into EtOAc, which was washed to remove 
residual DMF and dried over MgSO4. Solvent evaporation afforded a pure clear oil 19 in 96% according 
to 1H NMR analysis.    
 
Scheme 19: Phenolic sulfenylating agent 19. 
The 1H NMR of 19 revealed two sets of AB doublets in the aromatic region corresponding to two 
aromatic groups as H-4, H-3, H-9 and H-10 (see Figure 17 for numbering). A broad singlet at 3.38 ppm 
was observed for the phenol hydroxyl, two methylene triplets for H-7 and H-6 and another singlet at 
2.45 ppm for H-1. Finally, the distinct aliphatic singlet for the H-1 methyl group provided evidence of a 
successful coupling reaction to form 19.   
The 13C NMR spectrum of 19 revealed four aromatic singlets for the C-H carbons of which two 
belonged to the phenol ring and the other two to the thiotosylate core. In addition, four relaxed 
quaternary carbons were observed together with 3 aliphatic carbons at 37.6 ppm, 34.4 ppm and 21.8 












ppm) offered more evidence of coupling and consistent with the formation of a C-S bond. The IR 
spectrum of 19 indicated the presence of the tosylate group (-RSO2R-) at 1228 cm-1 and also a phenol 
(ArOH) at 3152 cm-1. High resolution mass spectrometry (HRMS) corroborated the molecular weight as 
found, (ES) m/z: 309.0615 [M+H] +, C15H17O3S2 requires 309.0619, thus confirming product formation. 
 
Figure 17: 1H NMR spectrum of 19 in chloroform-d3. **: Solvent impurities, *: impurity 
 
3.2.2 PMB Vinyl thioacetate, 2335  
With the right-hand fragment in hand we then turned our attention to the left-hand fragment. From the 
retrosynthetic analysis it was identified that the required vinyl thioacetate 23 could be accessed in two 
steps from commercially available p-methoxybenzyl chloride 11 as the starting material. The synthesis 
of 23 will now be described in detail. 
 
3.2.2.1 PMB Alkyne, 2235 
Adhering to the UCT synthesis as described previously in Chapter 2, the synthesis of the desired vinyl 
thioacetate 23 intermediate (see Scheme 20) began with the preparation of the p-methoxybenzyl thiol 
21 which was achieved from commercially available p-methoxybenzyl chloride 11 using the thiourea 
methodology. The reaction was initiated by refluxing 11 with thiourea (1.2 mol equivalents) in 
acetonitrile. The donation of the lone pair on nitrogen enhances the nucleophilicity of the thiourea 
sulfur, which undergoes nucleophilic attack on the reactive benzyl halide to form the isothiouronium salt 
20. The salt 20 proved to be very polar and only migrated slightly on TLC in a polar medium such as 












methoxybenzyl chloride and had reached completion within an hour and a half. Upon cooling, the 
thiouronium salt crystallised out of solution, and it was then filtered and washed twice with ice-cold 
acetonitrile and dried. The salt 20 was carried forward to the subsequent step without any further 
purification, in which it was dissolved in degassed MeOH at 0°C containing 2.5 equivalents of KOH. 
Therafter, propargyl bromide was added for the in situ propargylation of the thiol. Urea was produced in 
the reaction as a by-product. It was necessary to use 2.5 equivalents of KOH to completely hydrolyse 
the isothiouronium salt 20 to the corresponding thiol as well as to neutralise the HBr generated from the 
propargylation step. The propargylation step proved to be rapid, and reached completion within 40 
minutes as seen by the appearance of a less polar product spot on TLC compared to the salt 20. The 
product was purified by column chromatography to afford the alkyne 22 as a light-yellow pungent oil in 
90% yield over the two steps. 
 
Scheme 20: Synthesis of the propargyl thioether 22.  
 
Evidence for propargylation was given by the appearance of a doublet at 3.08 ppm for H-6 that 
integrated for two protons, as well as a triplet at 2.28 integrating for one proton corresponding to H-8. 
Interestingly, the two signals had a common coupling of 2.6 Hz that indicated transmission through the 
triple bond C-6 and C-8. Analysis of the 13C NMR spectrum of 22 revealed the alkyne carbons 
resonating at 80.1 ppm and 71.3 ppm corresponding to C-7 and C-8 respectively. Two methylene 















3.2.2.2 Vinyl thioacetate, 2335  
The second step in the synthesis of vinyl thioacetate 23 involved the regioselective addition of 
thiolacetic acid to the terminus of alkyne 23 (see Scheme 21). The reaction was carried out by 
dissolving alkyne 23 in dry, degassed toluene and heating to 85°C. The radical initiator ACCN (0.1 
equivalents) was added to the solution followed by the drop-wise addition of thiolacetic acid (1.2 
equivalents) in toluene over 20 minutes. The temperature was cautiously maintained at 85°C, as it was 
thought that higher temperatures would favour further additions of thiolacetic acid to form the bis-
substituted 23a product. After an hour, TLC analysis revealed the formation of a more polar spot and 
substantial depletion of the starting alkyne 22. Upon cooling, saturated aqueous sodium carbonate was 
added to the solution to quench any remaining thiolacetic acid. The toluene solvent was removed under 
vacuum and the residue extracted into DCM and dried over MgSO4. The product was purified by 
column chromatography to afford vinyl thioacetate 23 in 62% yield as a ~ 1:1 mixture of Z: E isomers 
that were inseparable. 
 
Scheme 21: Regioselective radical addition of thiolacetic acid to form vinyl thioacetate 23.   
 
The 1H NMR spectrum of 23 revealed overlapping signals for both isomers that could not be 
distinguished easily. However, two vinyl doublets of triplets (allylic coupling to H-5) were observed 
downfield at 6.67 ppm and 6.50 ppm corresponding to H-3 of the E- and Z-isomers respectively (see 
Figure 18 for numbering) proving that addition had taken place on the terminus of alkyne 22. The two 
isomers displayed different vicinal coupling constants between H-3 and H-4, which were 15.6 Hz for the 
E- and 9.6 Hz for the Z-isomer respectively. The H-4 signals were observed as an overlapping doublet 
of triplets ranging between 5.80 ppm and 5.87 ppm as they coupled to both H-5 and H-3. The H-5 peak 
appeared as a set of doublet of doublets accounting for both isomers that experienced coupling to both 
the vicinal H-4 and the allylic H-3. Other peaks were used to correctly identify the product included two 
acetyl singlets at 2.38 ppm and 2.36 ppm.   
The 13C NMR spectrum showed all the 26 required carbon signals (13 for each isomer) whereby two 
downfield signals were observed at 193.1 ppm and 191.4 ppm corresponding to the thioacetate 
carbonyl (C-2) of the E- and Z-isomers respectively. 2 sets of: two aromatic C-H carbons, two aromatic 












were observed for the two isomers. As the latter couldn’t be separated by chromatography, HSQC was 
used to assign the signal for each one. 
 
Figure 18: 1H NMR spectrum of 23 in chloroform-d3. 
 
3.2.3 PMB-phenol Disulfide, 25 
The coupling (see Scheme 22) of vinyl thioacetate 23 with the sulfenylating agent 19 to afford the core 
vinyl disulfide pharmacophore was a critical step in the synthesis of the target molecule 6. This was 
achieved by vinyl thioacetate deprotection to its corresponding enethiolate ion 24 by hydrolysis with 
KOH in MeOH at -40°C. The reaction was kept at -40°C to retard the highly reactive enethiolate 24 
from forming side products or reducing the possibility of tautomerism to the thermodynamically more 
stable E-isomer. The reaction was allowed to proceed for 45 minutes at -40°C after which it was cooled 
further to -78°C before adding the sulfenylating agent 19 (1.3 equivalents) dissolved in DCM (as a co-
solvent) to the reaction mixture. TLC analysis was performed after an hour to reveal a dominant, more 
polar spot than the vinyl thioacetate, with reduction in intensity of the spot for the sulfenylating agent. 
Overall, it was found that an hour and a half for this step was sufficient time to achieve good yields. The 
reaction was quenched at -10°C with saturated ammonium chloride prior to being extracted, and the 
residue purified by column chromatography to afford the coupled product 25 as a 5:4 mixture of E/Z-













Scheme 22: Coupling of 19 and 23 to form vinyl disulfide 25. 
 
Surprisingly, there appeared to be a slight geometry reversal about the double bond, from ~ 1:1 in the 
vinyl thioacetate 23 to 5:4 (E/Z) in the vinyl disulfide 25. The following (see Scheme 23) serves as a 
proposed pathway to explain the geometry shift. The enethiolate may undergo proton exchange with 
methanol to form the enethiol, which tautomerises to the corresponding thioaldehyde. Subsequent free 
rotation about the C-1/C-2 single bond to minimise steric strain followed by a second tautomerism to 
the thermodynamically more stable E-enethiol, followed by deprotonation by methoxide would then 
produce the E-enethiolate for reaction with the sulfenylating agent to form the stable E-vinyl disulfide 
25.   
 












The structure of 25 was confirmed by its 1H NMR spectrum (see Figure 19), which revealed the 
characteristic signals from both coupling partners. However, the S-acetyl methyl peaks of each isomer 
of the vinyl thioacetate group were not present at 2.38 ppm and 2.36 ppm, nor were the thiotosylate 
aromatic and methyl protons at 7.81, 7.34 and 2.45 ppm respectively. Interestingly, the signal for H-3 of 
the E-isomer (5.88 ppm) was slightly more downfield than that of the Z-isomer (5.70 ppm); this was a 
larger difference than that observed in 23. The isomers were again distinguished by their coupling 
constants for H-4 which was 14.6 Hz and 9.6 Hz for the E- and Z-isomers respectively. H-3 has two 
vicinal couplings, while H-4 has an allylic and a vicinal coupling. Lastly, the four aromatic signals for the 
phenyl groups were observed.  
 
The 13C NMR of 25 revealed two downfield peaks at 158.8 ppm and 154.3 ppm corresponding to C-14 
and C-10 respectively. Four C-H aromatic carbon peaks were observed at 130.2, 129.9, 115.6 and 
114.1 ppm each corresponding to C-12, C-8, C-9 and C-13. Both C-9 and C-13 experienced shielding 
by the phenol and methoxy groups respectively. Two quaternary carbons were observed at 132.2 ppm 
and 130.7 ppm corresponding to C-7 and C-11 respectively. Two vinyl signals were observed, whereby 
their peaks were correlated to their corresponding proton signals by HSQC. Four aliphatic signals were 
also observed within their excepted regions and also methoxy signal. The product was obtained as a 
mixture of isomers in which some peaks overlapped and could not be assigned to individual isomers. 
However, all the required 38 carbons were identified (19 for each isomer). The IR spectrum of 25 
indicated the presence of the ArOH hydroxyl group at 3152 cm-1 offering further evidence that coupling 
had taken place. High resolution mass spectrometry (HRMS) found (ES): m/z: 379.0849 [M+H] +, 
C19H23O2S3 requires 379.0860, thus confirming product formation.  
 













3.2.4 PMB-phenol Sulfoxide, 26 
The final step in the synthesis of the target sulfoxide 26 (see Scheme 24), involved the chemoselective 
oxidation of the sulfide 25 precursor. The oxidizing agent as m-CPBA (meta-chloroperbenzoic acid) 
displayed selectivity towards the sulfide over the vinyl disulfide functionality, which may be attributed to 
the greater nucleophilicity of the sulfide. 
 
 
Scheme 24: Chemoselective oxidation of disulfide 25 to form the sulfoxide 26. 
 
It was decided to use a slight excess of m-CPBA since one equivalent did not seem to promote full 
conversion of the starting material. This required that the temperature be kept below -60°C throughout 
the reaction to prevent over-oxidation. TLC analysis after an hour and a half indicated the appearance 
of a single, very polar spot that was believed to the sulfoxide product, along with the disappearance of 
sulfide 25. The reaction was quenched by the addition of saturated aqueous sodium carbonate, and the 
resulting solidified mixture allowed to warm up to room temperature. The residue was extracted and 
purified using column chromatography (EtOAc: Hexane = 75:25), to afford 26 as a 4:3 mixture of Z/E 
isomers as a clear oil in a yield of 68%. Minor bi-products were formed during the work-up which may 
have accounted for the modest yield observed. There was a slight geometrical shift of E to Z from 5:4 in 
sulfide precursor 25 to 3:4 in 26, and this may have been due to isomer differences in oxidation 
reactivity, particularly given the possibility of secondary oxidations (three sulfurs) occurring. 
The 1H NMR spectrum of sulfoxide 26 displayed significant deshielding effects compared to precursor 
25 (see Figure 20). The downfield shift of H-1 from 3.63 and 3.69 ppm in 25 to two singlets at 3.94 and 
3.96 ppm for the E- and Z-isomers respectively in 26, supported the site of oxidation as the sulfide 
sulfur. Similarly whereas the H-2 protons in the disulfide precursor 25 were observed as a doublet of 
doublets that appeared at 3.08 and 3.23 ppm for the E- and Z-isomers respectively, those for sulfoxide 












21 i), which creates a non-equivalent environment on C-2 and hence these protons H-2a and H-2b 
experience germinal coupling as diastereotopic protons. Thus, both H-2a and H-2b were observed as a 
double doublet of doublets (see Figure 21 ii) based on germinal, vicinal and allylic coupling. It would be 
thought that the protons on C-1 would manifest a diastereotopic relationship by virtue of being (α-) 
alpha to the chiral sulfoxide, but they did not split into the expected AB splitting pattern. Oxidizing from 
25 to 26 also resulted in a significant downfield shift in H-4 for both isomers from 6.08 ppm to 6.28 ppm 
for the E-isomer and 6.24 ppm to 6.56 ppm for the Z-isomer as a result of the resonance effect 
experienced between the sulfoxide and the vinyl double bond.  
The 13C NMR spectrum further supported the oxidation reaction, whereby there was a downfield shift of 
the methylene carbons α- to the sulfoxide. Thus, C-1 shifted from 35.6 ppm to 56.9 ppm in the Z-isomer 
and 34.8 ppm to 56.3 ppm in the E-isomer, while C-2 as the other carbon α- to the sulfoxide shifted 
from 29.5 ppm to 49.6 ppm in the Z-isomer and 32.9 ppm to 52.9 ppm in the E-isomer Interestingly, an 
upfield shift was observed for the carbon β- to the sulfoxide  (C-3) which may be attributed to the 
shielding effect of the sulfoxide’s oxygen. Also, C-11 as β- to the sulfoxide on the other side shifted 
from 130.7 ppm to 121.3 ppm for the E-isomer and 130.7 ppm to 121.4 ppm for the Z-isomer. The 13C 
was slightly complex due to the presence of the isomers; however, through HSQC analysis all the 
observed peaks were accurately correlated to their corresponding protons.  All the required nineteen 
carbons were observed for each isomer. The IR spectrum of 26 indicated the presence of the ArOH 
hydroxyl group at 3152 cm-1. High resolution mass spectrometry (ES) revealed a molecular ion peak 
(Figure 22) at 393.0646 corresponding to [M-H]+, which provided confirmatory evidence for the 













Figure 20: 1H NMR of 26 in chloroform-d3. 
 
Figure 21: (i) Inherent chirality of sulfoxide moiety. (ii) The (1) germinal, (2) vicinal and (3) allylic 





































Chapter 4: Increasing the Aqueous Solubility of Substituted 
Ajoenes 
4.1 Introduction  
 
Following the successful synthesis of sulfoxide 26 (6, R = H), attention was then turned towards 
substituting the phenolic hydroxyl group with substituents that would promote the aqueous solubility of 
the ajoene molecule. The substituents were chosen as acetyl, methoxycarbonylmethylene as well as 
the corresponding amide based on hydrogen-bonding characteristics as well as ease of introduction. 
For simplicity the new targets are referred to as PMB-acetate 27, PMB-Ester 28 and PMB-Amide 29 
(see Figure 23). Their synthesis and characterisation will be described next. 
 
Figure 23: Ajoene targets with increased aqueous solubility. 
4.2 PMB-Acetate, 27 
 
The first target, 27, was prepared by acetylation of the free phenol (see Scheme 25), by dissolving 
sulfoxide 26 into DCM and adding NEt3 (triethylamine) as the base, DMAP (dimethylaminopyridine) (0.1 
equivalents) as an acyl transfer agent followed by the addition of acetyl chloride (1.3 equivalents) at -
20°C. TLC analysis revealed the formation of a less polar product spot within 20 minutes of reaction 
time accompanied by complete consumption of the starting material. The reaction proceeds rapidly due 
to the formation of a highly electrophilic, positively charged N-acylpyridinium intermediate species 
formed between DMAP and acetyl chloride, which reacts fast (faster than acetyl chloride itself) with the 
phenol via a nucleophilic acyl substitution reaction (SNAc). 1M HCl was added to the reaction mixture to 
remove the NEt3 and DMAP and the solution extracted with ethyl acetate before being washed by 
aqueous sodium bicarbonate to remove acidic residues. The residue obtained after extraction and 
drying was purified by column chromatography to produce 27 as a yellow solid as a 3:4 mixture of Z/E 












combustion analysis, in which the best outcome was C found as 53.45% and H as 6.33% when C 
57.77% and H 5.54% were required. The sample was left on the vacuum pump for several hours, was a 
single spot on TLC but returned a 1H NMR spectrum that showed a small impurity in the highfield 
region – see Figure 24. Similarly, the melting point was found to be fairly sharp at 45 - 47°C (there are 
isomers). Final confirmation of structure was provided by 1H and 13C NMR spectroscopy, IR and HRMS. 
 
Scheme 25: Substitution of PMB-phenol 27 by acetyl chloride. 
The 1H NMR spectrum for the PMB-acetate 27 (see Figure 24) confirmed that the desired substitution 
had been achieved owing to signals of the phenol 26 being observed, together with a new singlet at 
2.28 ppm for both Z/E-isomers corresponding to the acetyl methyl group of the acetate. The aromatic 
signals for H-12 and H-8 overlapped between 7.17 and 7.24 ppm, while the shielded H-9 and H-13 
resonances ortho to the electron-releasing oxygen-based groups were clearly separated and with H-13 
assigned as the most upfield of the two owing to the greater donating ability of the methoxy group.  
 In the 13C NMR spectrum, a peak at 169.6 ppm was observed corresponding to the ester carbonyl 
carbon C-1`. An upfield shift of C-10 was observed from 155.2 ppm (in 26) to 149.5 ppm due to the new 
acetyl group. There was a downfield shift from 131.0 ppm to 137.3 ppm experienced by C-7, and 
further evidence to support product formation was a new aliphatic signal at 21.2 ppm for the C-2` ester 
methyl group. In addition, the presence of the carbonyl was confirmed by a carbonyl stretch in the IR 
spectrum at 1700 cm-1. HRMS (ES) revealed a molecular ion peak at 437.0910 corresponding to [M+ 













Figure 24: 1H NMR of 27 in chloroform-d3. *: impurity 
4.3 PMB-Ester, 28 
 
The second target was accessed via O-alkylation of the sulfoxide 26 through an SN2 reaction (see 
Scheme 26). The sulfoxide was dissolved into THF and NaH (sodium hydride) added to the solution at -
20°C. This afforded the sodium phenoxide ion with evolution of hydrogen gas, which was then reacted 
with methyl bromoacetate (1.4 equivalents). The reaction was allowed to warm to room temperature 
over 45 minutes, which produced one major product spot (by TLC) that was only marginally less polar 
than the starting material, and in which a double TLC development was required for it to become 
visible. The chemoselectively displayed in the substitution reaction, i.e attack at the methylene rather 
than the ester carbonyl was due to the greater electrophilicity of the methylene carbon due to the 
presence of two electron-withdrawing groups.  This, coupled with the weaker C-Br bond compared with 
the C-O bond, steered the reaction. Aqueous ammonium chloride was added to quench the reaction 
and the product extracted with ethyl acetate, which was dried over MgSO4 and the residue after solvent 
evaporation purified by column chromatography to afford 28 as a clear oil and as a 1:1 mixture of Z/E 
isomers in 85% yield.   
 












The 1H NMR spectrum for the PMB-ester 28 revealed an interesting upfield shift of the H-9 signal (see 
Figure 24 for numbering) from 7.01 ppm in acetate 27 to 6.83 ppm in 28, which was attributed to the 
greater donating ability of the oxygen in ester 28 compared to that of the acetate 27, where there is 
resonance with the carbonyl group. A set of new methylene singlets observed downfield at 4.60 ppm 
and 4.61 ppm offered evidence for a successful O-alkylation. This was supported by the appearance of 
additional methoxy signals at 3.80 ppm corresponding to the ester. All the other signals for the core 
structure were also observed and used in discerning the structure of the product. 
In the 13C NMR spectrum of 28, a peak was observed at 169.5 ppm corresponding to the ester carbonyl 
carbon for both Z/E- isomers. A signal for the methylene C-1` was observed at 65.6 ppm which offered 
evidence that it was adjacent to an electron-withdrawing oxygen. The methoxy C-1” signal was 
observed at 52.3 ppm. HSQC was used to identify all the 38 signals required for both isomers (19 each) 
correlating to their corresponding protons. In addition, the presence of the carbonyl was confirmed by a 
distinct carbonyl stretch in the IR spectrum at 1700 cm-1. HRMS (ES) revealed a molecular ion peak at 
467.1004 corresponding to [M+H]+ (see Figure 25), providing confirmatory evidence for the product, 
since C22H27O5S3 requires 467.1021. The peak at 489.0828 is due to [M+Na]+ as a result of using 
electronspray ionization. 
 















4.4 PMB-Amide, 29 
 
For synthesis of amide 29 it was initially thought that the reaction could be carried out in the same 
manner as synthesis of the PMB-ester 28, except to change the electrophile to 2-iodoacetamide, (see 
Scheme 27 i), formed from iodide exchange on 2-chloroacetamide. This reaction, however, proved to 
be much slower as it was observed that after 45 minutes at room temperature only ~10-20% of the 
starting material had been converted into a more polar product, as seen by TLC analysis. Allowing the 
reaction to proceed longer at room temperature, did not improve the conversion. It was evident that the 
phenoxide ion had formed as hydrogen gas was evolved upon NaH addition, and thus it was assumed 
that this was not the reason for the rate reduction but rather the subsequent O-alkylation. The reaction 
was also refluxed at 65°C, which unexpectedly caused a fragmentation of the ajoene molecule at the S-
S bond, confirmed by 1H NMR analysis of the isolated products.  
 
Scheme 27: Synthesis of the PMB-amide, 29. 
From a room-temperature reaction as shown in Scheme 27 (i), the PMB-amide was isolated as a solid 
in 15% yield as a 1:12 mixture of Z/E isomers. Noticeable was the major geometrical shift of Z to E from 
3:4 in the sulfoxide 26 to 1:12 in the PMB-amide 29. It was postulated that this may have been due to 
one of the relatively acidic protons α- to the sulfoxide undergoing deprotonation by the NaH to form a 
delocalised allylic anion. Such a species (see Scheme 28) might then have a reduced energy barrier to 
rotation of the C-3-C-4 double bond resulting in overall isomerization to the favoured E-form with less 
steric strain compared to the Z-. Protonation (eg on work-up) would then regenerate the allyl sulfoxide 












     
Scheme 28: Geometrical shift Suggested mechanism for isomerisation of PMB-amide 29.  
It is known that the Z-isomers of ajoenes are biologically more active and thus it was crucial to use a 
synthetic route that would retain Z-configuration integrity.35 Thus, other bases to access PMB-amide 29 
were considered and so a weaker base was used, since the rate-determining step was presumably the 
alkylation step. 
K2CO3 (potassium carbonate) in acetonitrile was chosen as an appropriate base for reaction. To this 
end, the sulfoxide 26, K2CO3, and 2-iodoacetamide (2.0 equivalents) were dissolved into acetonitrile at 
room temperature and the reaction mixture was heated to 45°C (see Scheme 27 (ii)), as it had been 
noticed that the reaction was not progressing at room temperature in a similar experiment. The 
potassium phenoxide was thought to be more reactive than its sodium counterpart, but TLC monitoring 
only showed significant starting material consumption at 10 hours at (room temperature). Heating the 
reaction at 45°C overnight in an attempt to consume all the starting material did not improve the 
conversion, and thus at this point the reaction was quenched with aqueous sodium bicarbonate and the 
product isolated in the conventional manner using extraction followed by chromatography to afford the 
amide 29 as a 3:1 mixture of Z/E isomers as a light-yellow solid in an improved 45% yield. The 
aforementioned explanation of the isomerization when using sodium hydride as base is supported by 
this result in that K2CO3 is too weak to deprotonate - to the sulfoxide. The Z-isomer enrichment may 
be explained by the repeated chromatography as well as problems with separating the E-isomer from 
unreacted 2-iodoacetamide, which had the same polarity. The reduced reactivity in the reaction 
compared to that for 28 may be attributed to the nature of the electrophile, as the amide group is not as 
electron-withdrawing as its ester counterpart owing to back-donation by nitrogen. This results in a lower 













combustion analysis data but the melting point was found to be quite sharp at 86 - 88°C. Overall 
confirmation of structure was provided by 1H and 13C NMR spectroscopy, IR and HRMS. 
The 1H NMR spectrum for the PMB-amide 29 resembled that of the PMB-ester 28, except two 
diagnostic NH amide peaks were observed as two broad singlets at 6.53 and 5.72 ppm indicating their 
existence in different magnetic environments, since amides have partial double-bond character with 
restricted rotation about the C-N bond. Methylene singlets were observed at 4.47 ppm corresponding to 
H-1’ for both isomers (see Figure 26 for numbering). As with the other derivatives 27 and 28, diagnostic 
signals for the allyl sulfoxide moiety (H-2 to H-4) could be readily identified for each isomer. 
The 13C NMR spectrum offered more evidence for a successful O-alkylation, whereby it revealed a 
downfield peak at 171.0 ppm corresponding to the amide carbonyl C-2’ for both isomers. Two sets (for 
the isomers) of four C-H aromatic peaks were observed at 131.3, 129.8, 115.0 and 114.7 ppm each 
corresponding to C-12, C-8, C-9, and C-13 respectively. Two sets of four quaternary carbons were 
observed at 160.0, 156.7, 133.0 and 121.7 ppm corresponding to C-14, C-10, C-7 and C-11 for both 
E/Z-isomers. Similarly, two sets of two vinyl carbons were observ d corresponding to C-3 and C-4, and 
also the four aliphatic carbons as C-1, C-2, C-5 and C-6. The methylene C-1’ carbon adjacent to the 
phenolic oxygen resonated at 65.6 ppm. HSQC was used to identify all 21 carbons (as 17 resonances) 
for each isomer, correlating to their respective protons. The amide carbonyl was also identified by IR 
spectroscopy in which a carbonyl stretch was observed at 1688 cm-1, as well as NH stretches at 3524 
and 3401 cm-1. High resolution mass spectrometry (ES) revealed a molecular ion peak (Figure 27) at 
452.1026 corresponding to [M+H]+, which provided confirmatory evidence for the formation of the 
product, as C21H26NO4S3 requires 452.1024.  
4.5 Overview and Comments 
 
The synthesis of an ajoene analogue with an amide group substituent on the “right” side of the 
molecule proved to be a non-trivial task. The success of the synthesis is attributed to long reaction 
times using a mild base, and repeated chromatography was required to purify the product from 
unreacted excess 2-iodoacetamide, which had the same polarity as the product making it difficult to 
monitor the reaction progress with ease. The other analogues were successfully achieved in good 
yields via an assisted O-acylation using DMAP for the acetate analogue and a nucleophilic substitution 
(O-alkylation) for the ester analogue.     
The biological activity and aqueous solubility of each analogue were evaluated and the results are 













Figure 26: 1H NMR spectrum of PMB-amide 29 in chloroform-d3. 
 
 














Chapter 5: Biological and Solubility Evaluation of the Substituted 
Ajoenes 
5.1 Determination of the IC50 of Ajoene analogues 
 
To determine whether the novel ajoene analogues displayed any tumour-cell cytotoxic effects, each 
analogue was tested against two cancer cell lines for its capability to inhibit cell proliferation. The assay 
employed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to evaluate the  extent to 
which each compound affected cell viability by spectrophotometrically measuring the reduction of 
yellow tetrazolium MTT to the crystalline purple formazan (see Scheme 29). The mitochondrial 
reductase enzymes in metabolically active cells are known to facilitate this reduction, and thus the 
concentration of formazan falls away as cells are killed by the ajoene being tested. The MTT reagent 
was added to cells that had been previously treated with varying concentrations of each ajoene 
analogue for a few days and the resulting formazan was solubilised in a 10% aqueous sodium lauryl 
sulfate (SLS) solution. The concentration of the formazan dye was measured spectrophotometrically 
using a scanning multi-well plate reader as an absorbance at 595 nm. A dose-response curve was then 
generated, from which an IC50 value for each compound was extrapolated. The IC50 is defined as the 
compound concentration required to inhibit 50% of the (cancer) cell population.50   
 
Scheme 29: Reduction of MTT to formazan by viable cells. 
The analogues were each assayed for their ability to inhibit cell proliferation in two cancer cell-lines, 
namely: An A375 human malignant melanoma epithelial cell-line and a WHCO1 oesophageal epithelial 
cancer cell-line, which had displayed good sensitivity to other ajoene analogues synthesized previously 
in our group.35 Since the ajoene analogues were synthesized as a non-separable mixture of E/Z-












The IC50 values for each ajoene analogue tested are shown in Table 2. The activities of all the new 
synthesized analogues were comparable to the advanced lead 5 that had been identified in an SAR 
study conducted within our group.35 It is important to note that the results of the assay were influenced 
by the cell density, as treating cells that had reached (or near) full confluence returned a less 
pronounced effect. This finding supported the suggestion proposed by Xiao and co-workers that ajoene 
and related compounds are selective for mitotic cells and as such, all the IC50 values were determined 
only on growing cells.51  
The IC50 values of the new analogues against the WHCO1 cell-line were each comparable to that of the 
bis-PMB 5 (2.5 M) used as the prototype, again offering further evidence that the cancer cell anti-
proliferation activity of ajoene resides within the vinyl disulfide/sulfoxide core.35 The newly formed 
analogues had enhanced polar character due to substitution by polar groups on the right-hand 
terminus; these did not have any detrimental effects on the anti-proliferation activity. The PMB-ester 28 
with a methoxycarbonylmethylene substituent was the most active of the four new analogues against 
both the WHCO1 (1.7 M) and A375 cell-lines (9.3 M) (see Table 2 and 3 for representative IC50 
curves). 
Table 2: IC50 Data for Ajoene Analogues (in M) 
Analogue as E/Z-mixture A375  WHCO1 
Bis-PMB, 5 9.4 2.5 ± 0.7; n = 3  
PMB-Phenol, 26 9.4 1.9 ± 0.8; n = 3 
PMB-Acetate, 27 16.5 3.6 ± 0.04; n = 3 
PMB-Ester, 28 9.3 1.7 ± 0.9; n = 3 
PMB-Amide, 29 13.0 7.7 ± 1.7; n = 3 
n = number of repeated experiments 
The next section discusses the solubility studies and the animal study carried out on one of the 
















Table 3: Representative dose-response Curves for the Ajoene Analogues 
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5.2 Assessment of Aqueous Solubility by Measuring Turbidity 
 
The turbidimetric solubility assay used in this work was developed by Van de Hulst and Hongve, which 
is used in modern times by the pharmaceutical industry in the rapid screening of libraries (allied with 
Lipinski rules).59 It is based on the fact that precipitated particles formed at the onset of solubility scatter 
light resulting in an Absorbance that can be measured. The intensity of the scattered light is dependent 
on the concentration of scattering particles, and the turbidity is measured using a UV-vis 
spectrophotometer at 620 nm. Testing of a compound required dissolving it in high purity DMSO then 
added to an aqueous solvent (0.01 M Phosphate-buffered saline (PBS) at pH 7.4) to evaluate its 
solubility. The point at which the solution becomes turbid is regarded as that at which the compound is 
insoluble in the PBS solution and it is at this point that particle precipitation leads to an increase in 
absorbance (from 0) related to the concentration of the sample.56, 57   
Sample preparation starts by making up a stock of the test compound in high purity DMSO into a 300 l 
solution of 10 mM. A predilution plate is made up in a 96 well-plate with solutions with 10, 8, 4, 2, 1, 0.5, 
0.25 and 0mM of the stock in 100 l in triplicate and these are used to make up the test solutions. To 
prepare 200 l of each solution containing 200, 160, 80, 40, 20, 10, 5 and 0 M in both DMSO and 
PBS, 4 l of each of the predilution solutions was added to 196 l of both DMSO and PBS in triplicate. 
The samples were incubated for 2 hours at 37°C and analysed on the SpectraMax 340PC UV-vis 
spectrophotometer, and the results are summarised in Figure 28.  
. 



















Concentration ( M) 


















Turbidimetric analysis of the new analogues indeed revealed an increase in aqueous solubility 
compared to the bis-PMB, which became turbid at a concentration of about 20 M. Surprisingly, the 
scattering with increased concentration of this analogue (as seen from the increase in A) did not 
increase as much as that of the phenol and the ester analogues which become turbid at similar 
concentrations. Reasons for the discrepancy are unclear at this stage.   
The amide 29 and acetate 27 analogues were the most soluble of the four analogues from this thesis, 
as their scattering (A > 0) was observed at a concentration of 40- 50 M indicating their promoted 
solubility in the aqueous medium as compared to the bis-PMB, which may be attributed to their 
hydrogen-bonding characteristics. 
5.3 Animal study (in vivo) 
 
The study was conducted by Dr Catherine Kaschula from the UCT IIDMM (Institute of Infectious 
Diseases and Molecular Medicine) to assess the in vivo activity of the PMB-amide 29, which was 
chosen to be a suitable candidate based on its polar nature. Based on the solubility data, the latter was 
considered as having a good enough solubility for delivery into the mouse subject, since one of the 
objectives was to enhance the aqueous solubility of the ajoene molecules. There are reports in the 
literature that suggest that compounds with phenols may be toxic to subjects as they form reactive 
metabolites. Similarly, phenolic acetates (27) could be hydrolysed to the phenol, and the PMB-ester 28 
could also be hydrolysed (to its acid form), which would also probably be toxic. All these factors 
suggested that the other three analogue  were not as suitable candidates as amide 29.52 
The study comprised of 20 nude mice, which each received a subcutaneous injection of 2.50 x 105 
A375 cells (in 100 L of PBS) into their hind right quarter. The mice were split into two groups of 10 
mice assigned to the treatment or the control group and the tumours were allowed to grow for 21 days. 
The test mice each received PMB-amide (8mg/kg) from the day of inoculation every day for the 
duration of the study by intraperitoneal injection, in which the drug was solubilised easily into a solution 
of 2.5% chondroitin, 10% DMSO and PEG400. The tumours were measured twice weekly and recorded 
as a tumour volume (volume calculated by: (length2 x height)/2).53 Upon completion of the study on day 
21, the mice were sacrificed (halothane inhalation), the tumours were removed and accurately weighed 













Figure 29: A steady increase in weight of the mice from the treatment and control groups was 
observed over the duration of the study which indicated that the drug was not cytotoxic to the mice. 
 
The results revealed that treatment with the PMB-amide had no significant effect on the tumour growth 
(see Figure 30) when compared with their control counterparts. From the collected data, it was 
apparent that there was no tumour volume reduction observed in the treatment group; rather the 
tumours steadily grew over time (see Figure 30 (i)). A similar result was observed for mice that were 






Figure 1: Figure 30: (i) Growth of tumours - Treated vs Untreated. Tumour size were 
measured by calipers (volume calculated by: (length2 x height)/2) 53; (ii) Tumour size as measured 
by weight of tumour obtained from biopsy. 
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The PMB-amide was ineffective at reducing tumour growth in the nude mice, yet it still had good in vitro 
activity. Upon initial design of this compound it was thought that its precursor bis-PMB 5 was ineffective 
due to its poor-bioavailability as a result of poor solubility in the intralipid solution used for drug delivery. 
The PMB-amide had a twofold increase in inherent solubility into the delivery solution compared to the 
bis-PMB 5 and as such it was administered in a solubilised form. Thus, the poor-bioavailability due to 
solubility was ruled out as an explanation for the failure. The two studies involving both bis-PMB and the 
PMB-amide have shown that administering of the drug via intraperitoneal injection is not the best 
method and as such oral or intravenous administration should be considered. However, owing to time 
constraints the other two methods could not be attempted.  Other experiments were carried out in an 
attempt to explain the ineffectiveness of the two compounds in reduction of tumours in nude mice and 
these were carried out at the Department of Pharmacology, UCT. The bis-PMB 5 was incubated with 
mouse whole blood in vitro at 37°C and the amount of compound present in the sample monitored over 
three hours by removing an aliquot and analysing it by liquid chromatography-mass spectrometry 
(LC/MS), which gave a peak area as a reflection of ajoene derivative concentration. Concurrently, red 
blood cells (RBC) and blood plasma were separated and the same experiment conducted, and the 
results analysed, which are summarised in Figure 31.54 
 
Figure 31: Metabolic stability of bis-PMB in blood. 
The results from Figure 31 indicate that the bis-PMB incubated in both the whole blood and the red 
blood cells had strong affinity towards them and as such could not be detected in the two samples by 
LC/MS beyond 5 minutes of incubation, whereas in plasma alone it had a half-life of two hours. This 
data suggests that the bis-PMB possibly binds to the red blood cells and is thus not available for 
 Stability of bPMB in whole blood, plasma and RBC (37 C)
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delivery into the tumours when it is administered via intraperitoneal injection. However, further 
investigation needs to be carried out to support this hypothesis and to also evaluate exactly which 
receptors are likely responsible for the interaction observed. A study conducted by Apitz-Castro showed 
that ajoene (with the same vinyl disulfide/sulfoxide pharmacophore) has affinity towards the fibrinogen 
receptor, which is found in human platelets and prevents platelet aggregation. Thus, it is likely that the 
bis-PMB might bind to similar receptors reversibly, but this is still to be proven.55   
5.4 Ajoene analogues as Chemosensitizing agents  
 
The analogues described in this thesis were also tested in Professor Pani’s lab at the University of 
Cagliari (Institute for Virology and Microbiology) in Sardinia, for the possibility of chemosensitization 
defined as the reintroduction of sensitivity of an established anti-cancer drug towards a drug-resistant 
cancer strain. Hassan had shown that ajoene inhibits the anti-apoptotic bcl-2 protein in acute myeloid 
leukaemia (AML) cells resulting in the release of cytochrome c into the cytosol and the activation of 
caspase-3 which ultimately leads to an apoptotic response.12b In the study they observed that addition 
of ajoene with two chemotherapeutic drugs fludarabine and cytarabine promoted sensitivity of the drug 
towards drug-resistant AML strains and this was attributed to inhibition of over-expression of anti-
apoptotic bcl-2 proteins by ajoene. Interestingly, the ajoene on its own failed to promote either the 
inhibition of the bcl-2 or the induction of apoptosis in the AML cells implying that ajoene’s anti-tumour 
activity wasn’t a prerequisite for chemosensitization.   
 
The cytotoxicity of a library of ajoene analogues synthesized (5, 26-29 as well as some ajoenes with 
alkyl end-groups) was analysed against hematologic and solid tumour cell-lines by an MTT assay as 
described in section 5.1 above and the results shown in Table 4. The analogues were not potent 
towards the CRL-7065 to the SK-MES-1 cell-lines as the required concentration to inhibit 50% growth 
was >30 µM. On the other hand they showed very good activity for the human acute T-lymphoblastic 
leukemia cells (CCRF-CEM), CCRF-SB, and the KBWT, kBMDR and the KBV20C cell-lines, particularly in 
comparison with established agents like Doxorubicin and Etoposide (see Table 4). Interestingly,  the 
PMB-allyl 32, acetate 27, ester 28 and PMB-phenol 26 were the more potent analogues tested, in 
which each of this group of analogues contained a lipophilic p-methoxybenzyl group that presumably 
promoted good permeability into the cells. The KBWT and the human nasopharyngeal carcinoma (which 
has stepwise selection for resistance with increasing concentration of vincristine) (KBV20C) cell-lines 
were selected for a chemosensitization assay, whereby the analogues were mixed with two 












































(E) Ajoene, 4 >30 >30 >30 >30 >30 >30 5.4 ± 0.5 6.3 30.8 ± 5 50.7 ± 17.2  35.8 ± 1.6 
(Z)  Ajoene, 4  >30 >30 >30 >30 >30 >30 6.2 ± 0.7 6.4 22.0 34.1 ± 12.4  22.0 ± 2.4 
(E)Propyl-Allyl, 30 >30 >30 >30 >30 >30 >30 2.3 ± 0.2 5.7 13.2 ± 1.1 28.8 ± 5.5  18.8 ± 1.1 
(Z)Propyl-Allyl, 30 >30 >30 >30 >30 >30 >30 3.1 ± 0.4 5.7 23.1 ± 2.6 34.9 ± 5.3  23.3 ± 1.3 
(E)  Bis-Propyl, 31 >30 29.45 >30 >30 >30 >30 2.6 ± 0.5 6.0 19.6 37.7 ± 10.9  23.6 ± 1.2 
(Z) Bis-Proply, 31 >30 29.32 >30 >30 >30 >30  2.6 ± 0.5 3.2 14.4 ± 1.7 31.3 ± 3  16.7 ± 2.3 
(E/Z) PMB-Allyl, 32 >30 16.4 27.46 >30 >30 >30 1.3 ± 0.4 3.5 7.8 ± 0.6 13.8 ± 1.9  8.5 ± 1.7 
(E/Z) Bis-PMB, 5 >30 11.83 13.34 >30 >30 >30 0.8 ± 0.2 0.2 4.5 ± 1.3 7.4 ± 1.5  5.4 ± 1.0 
(E/Z) PMB-Acetate, 
27  >30 >30 9.65 >30 >30 >30 0.8 ± 0.1 3.1 3.5 ± 1.3 8.2 ± 0.7  4.8 ± 1.3 
(E/Z) PMB-Ester, 28  >30 >30 >30 >30 >30 >30 5.4 5.1 11.9 ± 1.7 21.8 ± 2.1  12.1 ± 1.3 
(E/Z)  PMB-Phenol, 
26   >30 >30 >30 >30 >30 >30 0.8 ± 0.1 3.1 4.4 ± 1.3 8.0 ± 1.2  5.4 ± 1.2 
p
6-MP       2.1±0.4 1.4±0.7     
q
CDDP       1.0±0.2 1.4±0.2     
Vincristine  0.015  2.6 >4 0.015 0.004±0.0008 0.012±0.0003 0.004±0.002 0.95±0.2 0.09±0.01 0.40±0.08 
Doxorubicin  0.44  0.3 1.1 0.21 0.12±0.06 0.05±0.03 0.4±0.08 ≥20 3.3±1 2.2±0.7 
r
Etoposide   4.6  7.6 7.8 2.04   3.3±1.1 ≥100 ≥100 7.6±2.5 
°Data represent mean values for three independent determinations.  
aCC50 : Compound concentration (µM) required to reduce the viability by 50%, as determined by the MTT method. 
bCRL-7065: skin fibroblasts 
cDU-145: human prostate carcinoma; 
dHela: human cervical adenocarcinoma;  
eHEP-G2: human hepatocellular carcinoma;  
fSK-MEL-28: human skin malignant melanoma;  
gSK-MES-1: human squamous cell lung carcinoma;  
hCCRF-CEM: human acute T-lymphoblastic leukemia;  
iCCRF-SB: human acute B-lymphoblastic leukemia;  
lKBWT: human nasopharyngeal carcinoma, wild type;  
mKBMDR: human nasopharyngeal carcinoma, multidrug resistent infected with a retroviral vector containing a full-length cDNA for the human MDR1 gene that conferred the full MDR phenotype; 
nKB7D: human nasopharyngeal carcinoma, stepwise selection for resistance with increasing concentration of etoposide;   
















The results showed both a synergistic and also an antagonistic effect when the analogues were 
mixed with the drugs DOXO and VCR. When compounds (E/Z)-ajoene 4, 30 (propyl - allyl) and 
the (E/Z)-bis-propyl 31 analogues were mixed with the two drugs and tested against the KBV20C 
cell-line which has resistance to VCR the results indicated an increase in resistance, i.e. 
negative chemosensitization.  Reasons for this antagonism are unclear. The opposite effect was 
observed for the PMB-allyl 32 to the PMB-Phenol 26. For the former, the CC50 of Vincristine (the 
concentration required to reduce viability by 50% of the KBV20C cells) was 0.85 M which 
decreased by eighteen fold to 0.047 M when 6.67 M of the PMB-allyl was combined with 
VCR. Of importance is that 6.67 M was below the CC50 of the PMB-allyl 32 of 8.5 M, meaning 
that the reduced CC50 of the drug in combination was not due to the ajoene derivative. This 
result indicated a synergy (positive chemosensitization) as it had been shown that the analogue 
alone had a CC50 of 8.5 M (see Table 4 and Figure 32).   
 
Figure 32: Representation of the chemosensitization effect of Vincristine and PMB-allyl against 
a VCR-resistant cancer cell-line.  
In the case when the PMB-allyl concentration was lowered to 2.22 M the required VCR was 
0.1 M showing that the synergistic effect as expected is ajoene-concentration dependent. This 
was still a healthy reduction in the CC50 of the drug. 
Similarly, the PMB-Ester 28 showed positive chemosensitization towards both DOXO 
(Doxorubicin) as well as VCR in KBWT (human nasopharyngeal carcinoma, wild type), with 
significant reductions in CC50 of the drugs at 8.33 M of 28 which is below the CC50 of 28 (11.9 
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Figure 33: The comparison of CC50 when PMB-Ester 28 is combined with both DOXO and VCR 
in KBWT. 
In addition, The PMB-phenol 26 showed significant chemosensitization activity at 3.33 M 
against the VCR-resistant cell-line KBV20C, and importantly at a concentration below its own 
CC50 (5.4 M in this cell-line, see Table 4 and Figure 34). In this regard it is useful to have a 
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Figure 34: The comparison of CC50 when PMB-Phenol is combined with both DOXO and VCR.   
These results show how addition of ajoene analogues switch on the sensitivity of the tumour 
cells towards the drug resulting in a reduction in the concentration of VCR required to achieve 
50% inhibition. Mechanistic and structural reasons for this are unclear at this stage but an 
empirical observation is that all positive ajoene chemosensitizers had at least one p-
methoxybenzyl group in their structure. This observation aids in the future design of 
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5.5 Overview and Comments 
 
All the synthesized ajoene analogues displayed good in vitro activity that was comparable to 
that of bis-PMB 5 which their design was based on. However, the analogue that was chosen for 
the in vivo assay returned a disappointing inability to reduce tumour growth in nude mice. Based 
on solubility studies, this is not believed to be due to poor solubility but rather either instability in 
blood and/or binding to red-blood cells. The compounds also demonstrated their ability as 
chemosensitization agents towards tumour cell-lines that are resistant to some marketed drugs 
such as Doxorubicin and Vincristine, which was attributed to the presence of at least one 




























Chapter 6: Summary and Future work 
The current thesis was aimed at improving the aqueous solubility of ajoene analogues for 
biological evaluation purposes. An SAR study identified bis-PMB 5 as the advanced lead that 
returned excellent in vitro activity, but failed to reduce tumour growth in an in vivo assessment. 
This was rationalised by identifying poor solubility of 5 as well as high reactivity of 5 as possible 
reasons. To this end, four new analogues were successfully synthesised in this thesis namely: 
PMB- Phenol 26, PMB- Acetate 27, PMB- Ester 28 and the PMB-Amide 29. Each returned an 
improved aqueous solubility as compared to the bis-PMB in which the acetate and amide 
analogues were the most soluble of the new analogues. Each of these analogues also had good 
in vitro activity that was comparable and superior to that of the bis-PMB (2.5 M) against the 
WHCO1 cell-line, with the PMB-Ester being the most active (1.7 M). 
The PMB-Amide 29 was chosen for the in vivo study in a nude-mouse model, which 
disappointingly failed to reduce tumour growth. This excluded poor solubility as a cause of the 
absence of bioactivity in vivo. Evidence suggested that 29 was binding to red-blood cells and 
not reaching the tumours. Future work will include administering the drugs via intravenous 
injection which would bypass the delivery problem. Various analogues were also tested for their 
ability to act as chemosensitization agents for the clinically approved chemotherapeutic drugs 
Doxorubicin and Vincristine against a drug-resistant cell-line. It was observed that analogues 
containing at least one p-methoxybenzyl substituent switched on the sensitivity of the tumours 
towards the drugs. 
It was thought that labelling the ajoene analogue would offer a unique opportunity to visualize 
the movement and localization of ajoene in cancer cells. However, attempts (not described in 
the thesis) to label the PMB-Phenol 26 with a radioactive 14C-tag failed to give the desired 
labeled products. A full investigation (at NECSA in Pelindaba, SA) could not be carried out 
owing to the lack of time. In the future, a different radioactive tag could be used to evaluate the 
localisation and metabolic fate of the ajoene analogue. An analogue with a radioactive amide 
substituent would prove to be very useful, see Figure 35.   
 












Chapter 7: Experimental Section 
7.1 General synthetic methods 
 
Thin Layer chromatography (TLC) was employed to monitor reaction progress utilising 
aluminium-backed plates that are coated with silica-gel F254. Compounds on TLC plates were 
visualised using ultra-violet light (254 nm), iodine vapour, or by spraying with a 2.5 % solution of 
anisaldehyde in a mixture of sulfuric acid and ethanol (1:10 v/v) and heating at 150 °C. Column 
chromatography was carried out using silica-gel (35-70 µm) on Biotage automated columns. 
Infrared spectra were recorded in chloroform or neat on an FT-IR spectrophotometer. Melting 
points were obtained using a Reichert-Jung Thermovar hot-stage microscope and are 
uncorrected. Elemental analyses were performed using a CHN elemental analyser. 1H and 13C 
NMR spectra were recorded at 400 MHz for 1H and 101 MHz for 13C in deuteriochloroform 
(CDCl3) unless stated otherwise. Chemical shifts are quoted using residual chloroform (δ 7.26 in 
1H NMR and δ 77.16 in 13C NMR) as an internal reference. All the chemical shifts are reported 
in ppm and coupling constants are quoted in Hz. High-resolution mass spectra were recorded 
on a Waters API Q-TOF Ultima machine, at the Mass Spectrometry Service, School of 
Chemistry, University of Stellenbosch.  
 All reagents and chemicals were commercially available. All the solvents used were purified 
and freshly distilled using standard methods prior to use. Degassed methanol as stated refers to 





















LiAlH4 (690.0 mg, 18.16 mmol) was suspended in THF (10 mL) at -20° C under N2, and methyl 
2-(4-hydroxyphenyl) ethanoate (1.00 g, 6.52 mmol) dissolved in THF (2 mL) added drop-wise to 
the rapidly stirring solution. The reaction was allowed to proceed for 2 hours after which a more 
polar spot was observed on TLC. Following the reaction 1M HCl (8 mL) was added slowly at 0° 
C to quench any remaining LiAlH4 and the solution was stirred for 20 minutes. The resulting 
solution was filtered through Celite, which was washed with EtOAc (40 mL) following drying of 
the extracts over MgSO4 and the solvent removed under vacuum, the residue was crystallised 
from hexane to afford 16 as a clear crystalline solid (828.0 mg, 92%): 
Rf = 0.3 (EtOAc: Hexane = 50:50); Mp (Hexane):86-88 °C, lit39 Mp: 87-89 °C; IR νmax/ cm-1 (KBr): 
3391 (ROH), 3152 (ArOH); δH (400 MHz,d6-acetone) : 8.00 (1H, brs, OH), 7.05 (2H, d, J = 8.4 
Hz, H-3), 6.74 (2H, d, J = 8.4 Hz, H-2), 3.69 (2H, t, J = 7.1 Hz, H-6), 3.53 (1H, brs, OH’), 2.71 
(2H, t, J = 7.1 Hz, H-5); δC (101 MHz, d6-acetone): 156.6 (C-1), 131.1 (C-4), 130.8 (C-3), 116.0 
(C-2), 64.3 (C-6), 39.6 (C-5). 
 
 
The alcohol 16 (800.0 mg, 5.77 mmol), imidazole (789.0 mg, 11.54 mmol), triphenylphosphine 
(3.041 g, 11.54 mmol) and iodine (2.943 g, 11.54 mmol) were dissolved in THF (7 mL) under N2 
at 0°C. The reaction mixture was allowed to warm up to room temperature over 2 hours, after 
which the alcohol spot had disappeared on the TLC (EtOAc: Hexane =30:70) and replaced by a 
less polar spot corresponding to the iodide. The solution was diluted with EtOAc (20 mL), and 
then saturated sodium thiosulphate (5 mL) was added. The contents were transferred into a 
separating funnel, the aqueous layer was further extracted with EtOAc (10 mL x 3), and the 
combined extracts were washed with 1 M HCl (10 mL), sodium bicarbonate (15 mL) and lastly 












purified by column chromatography (EtOAc: Hexane = 7:93) to afford 17 as a colourless solid 
(1.385 g, 97%): 
Rf = 0.7 (EtOAc: Hexane = 30:70); Mp (Hexane) :112-113 °C, lit40 Mp: 111-112°C; IR νmax/ cm-1 
(CHCl3): 3152 (ArOH), 500 (C-I);  δH (400 MHz,CDCl3) : 7.06 (2H, d, J = 8.6 Hz, H-3), 6.78 (2H, 
d, J = 8.6 Hz, H-2), 4.84 (1H,brs, OH), 3.31 (2H, t, J = 7.7 Hz, H-6), 3.10 (2H,t, J = 7.7 Hz, H-5); 





4-(-2-Iodoethyl)phenol 17 (1.350 g, 5.45 mmol) and potassium thiotosylate (1.604 g, 7.08 mmol) 
were dissolved in DMF (3 mL) and stirred at room temperature. The reaction was allowed to 
proceed for 2 hours, whereupon a spot-to-spot conversion was observed on TLC (EtOAc: 
Hexane = 20: 80), with the resulting product more polar than the starting 4-(-2-iodoethyl)phenol. 
The solution was then suspended in water (30 mL), which was extracted with EtOAc (15 mL x 
3). The combined extracts were washed with water (20 mL x 2) to remove any residual DMF. 
Following drying over MgSO4 and solvent evaporation a product as a clear oil was afforded 19, 
which was pure by 1H NMR spectroscopy (1.613 g, 96%): 
Rf = 0.4 (EtOAc: Hexane = 30: 70); IR vmax/cm-1 (CHCl3): 3152 (ArOH), 1228 (O=S=O); HRMS 
(ES) m/z: 309.0615 [M+ H] +, C15H17O3S2 requires 309.0619; δH (400 MHz, CDCl3) 7.81 (2H, d, J 
= 8.5 Hz, H-4), 7.34 ( 2H, d, J = 8.5 Hz, H-3), 6.95 (2H, d, J = 8.5 Hz, H-9), 6.74 (2H, d, J = 8.5 
Hz, H-10), 3.38 (1H, brs, OH), 3.18 (2H, t, J = 7.6 Hz, H-7), 2.83 (2H, t, J = 8.6 Hz, H-6), 2.45 
(3H, s, H-1); δC (101 MHz, CDCl3): 154.7 (C-11), 144.9 (C-2), 142.3 (C-5), 131.0 (C-8), 130.0 
















Thiourea (270.0 mg, 4.20 mmol) was dissolved in acetonitrile (7 mL) under N2 atmosphere and 
4-methoxybenzyl chloride (0.43 mL, 3.20 mmol) was added to the solution which was then 
refluxed for 2 hours. Reaction progress was monitored by TLC which showed formation of a 
more polar spot corresponding to the isothiouronium salt intermediate. The reaction was cooled 
in an ice-bath to afford a solid product that was filtered on a Bűchner funnel. The product was 
washed with ice-cold acetonitrile (25 mL) and dried further on the high vacuum pump to afford 
the crude isothiouronium salt (700.0 mg, 94%), Rf = 0.1 (EtOAc: Hexane = 2:3).  
The isothiouronium salt (700.0 mg, 3.02 mmol) was added to a rapidly stirring solution of 
potassium hydroxide (423.0 mg, 7.54 mmol) dissolved in degassed methanol (7 mL) at -20°C. 
After 30 minutes a less polar spot was observed on TLC (EtOAc: Hexane = 5:95) corresponding 
to the thiol. Propargyl bromide (0.47 mL, 80% in toluene, 5.29 mmol) was added drop-wise into 
the mixture and the reaction was warmed up gradually to room temperature. One major product 
spot on TLC was formed (EtOAc: Hexane = 5:95), which was less polar than the p-
methoxybenzyl chloride. The methanol was removed under vacuum, water (10 mL) was added 
and the residue was extracted into DCM (3 x 15 mL). The combined extracts were dried with 
MgSO4, solvent was removed under vacuum and the residue purified on silica-gel with (EtOAc: 
Hexane = 3:97) to afford 22 as a pungent oil, (522.0 mg, 90%): 
TLC: Rf = 0.4 (EtOAc: Hexane = 5:95); IR vmax/cm-1 (CHCl3): 3304 (C≡CH); δH (400 MHz, CDCl3) 
: 7.26 (2H, d, J = 8.8 Hz, H-3), 6.86 (2H, d, J = 8.8 Hz, H-2), 3.83 (2H, s, H-5), 3.80 (3H, s, 
OMe), 3.08 (2H, d, J = 2.6 Hz, H-6), 2.28 (1H, t, J = 2.6 Hz, H-8); δC (101 MHz, CDCl3) 158.9 
(C-1), 130.2 (C-3), 129.5 (C-4), 114.1 (C-2), 80.1 (C-7), 71.3 (C-8), 55.4 ( OMe), 34.9 (C-5), 















Alkyne 22 (522.0 mg, 2.72 mmol) was dissolved in toluene (7 mL) and the solution heated to 
85°C under N2. ACCN (68.0 mg, 0.27 mmol) used as a radical initiator was added to solution 
directly followed by the drop-wise addition of thiolacetic acid (0.23 mL, 3.26 mmol) in toluene (1 
mL). The reaction was carefully monitored by TLC (EtOAc: Hexane = 10:90), which revealed the 
formation of a more polar spot corresponding to the thioacetate after one hour. Allowing the 
reaction to progress a further 45 minutes in an attempt to consume all the starting material 
indicated the formation of an even more polar spot believed to be the bis-substituted product, 
23a. The solution was therefore cooled to room temperature and saturated sodium carbonate (5 
mL) was added to quench unreacted thiolacetic acid. Following removal of the toluene under 
vacuum, the remaining residue was extracted into DCM (10 mL x 3) and the combined extracts 
were washed with brine (10 mL x 2) then dried over MgSO4. The solvent was removed under 
vacuum and the resulting residue was purified by column chromatography (EtOAc: Hexane = 
10:90) to afford the ethanethioate product 23 as a ~ 1:1 mixture of Z: E isomers and as a light-
yellow oil (450.0 mg, 62%): 
(E/Z) mixture: TLC Rf = 0.6 (EtOAc: Hexane = 10:90); IR vmax/cm-1 (CHCl3): 1700 (C=O), 663 (C-
S) 
E-isomer: δH (400 MHz, CDCl3): 7.23 (2H, d, J = 8.3 Hz, H-8), 6.86 (2H, d, J = 8.3 Hz, H-9), 
6.50 (1H, dt, J = 15.6, 1.4 Hz, H-3), 5.81 (1H, dt, J = 15.6, 7.5 Hz, H-4), 3.80 (3H, s, OMe), 3.63 
(2H, s, H-6), 3.08 (2H, dd, J = 7.5, 1.2 Hz, H-5), 2.36 (3H, s, H-1); δC (101 MHz, CDCl3) : 193.1 
(C-2), 158.9 (C-10), 130.5 (C-4), 130.3 (C-8),130.0 (C-7), 119.5 (C-3), 114.1 (C-9), 55.4 (OMe), 
34.6 (C-6), 33.3 (C-5), 30.5 (C-1). 
Z-isomer: δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.3 Hz, H-8), 6.84 (2H, d, J = 8.3 Hz, H-9), 
6.67 (1H, dt, J = 9.6, 1.2 Hz, H-3), 5.86 (2H, dt, J = 9.6, 7.5 Hz, H-4), 3.80 (3H, s, OMe), 3.64 
(2H, s, H-6), 3.10 (2H, dd, J = 7.5, 1.2 Hz, H-5), 2.38 (3H, s, H-1); δC (101 MHz, CDCl3): 191.4 
(C-2), 158.9 (C-10), 130.3 (C-8), 130.2 (C-4),130.0 (C-7), 119.7 (C-3), 114.1 (C-9), 55.4 (OMe), 














The vinyl thioacetate 23 (226.0 mg, 0.84 mmol) was dissolved in methanol (1.5 mL), the solution 
was cooled to -40°C and stirred under N2. KOH (50.0 mg, 0.89 mmol) in degassed methanol (1 
mL) was added slowly and the reaction left stirring for 45 minutes, after which it was cooled 
down to -78°C. Sulfonothioate 19 (336.3 mg, 1.09 mmol) dissolved in DCM (2 mL) was added 
and the reaction was allowed to stir for an hour at -78°C before being allowed to warm up, after 
which a more polar spot than the starting vinyl thioacetate was observed on TLC (EtOAc: 
Hexane = 20: 80). The reaction was quenched with saturated ammonium chloride (5 mL), the 
solvents were removed under vacuum on the rotary evaporator, and the resulting residue 
extracted into DCM (15 mL x 3). The combined extracts were washed with brine (15 mL x 2) 
and dried over MgSO4. The product was purified using column chromatography (EtOAc: Hexane 
= 15: 85) to give a light-yellow oil 25 as a 5:4 mixture of E/Z isomers, (232.0 mg, 73%): 
(E/Z) mixture: TLC Rf = 0.6 (EtOAc: Hexane = 15:85); IR vmax/cm-1 (CHCl3): 3152 (ArOH), 663 
(C-S); HRMS (ES) m/z: 379.0849 [M+ H] +, C19H23O2S3 requires 379.0860. 
E-isomer: δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.5 Hz, H-12), 7.06 (2H, d, J = 8.5 Hz, H-8), 
6.85 (2H, d, J = 8.5 Hz, H-13), 6.76 (2H, d, J = 8.5 Hz, H-9), 6.08 (1H, dt, J = 14.6, 1.1 Hz, H-4), 
5.88 (1H, dt, J = 14.6, 7.4 Hz, H-3), 3.80 (3H,s, OMe), 3.63 (2H,s, H-1), 3.08 (2H, dd, J = 7.4, 
1.2 Hz, H-2), 2.93 (4H, m, H-5/6); δC (101 MHz, CDCl3): 158.8 (C-14), 154.3 (C-10), 132.2 (C-
7), 130.7 (C-11), 130.2 (C-12), 129.9 (C-8), 128.3 (C-3), 128.0 (C-4), 115.6 (C-9), 114.1 (C-13), 
55.5 (OMe), 39.9 (C-6), 34.8 (C-1 & 5), 32.9 (C-2).             
Z-isomer: δH (400 MHz, CDCl3): 7.23 (2H, d, J = 8.5 Hz, H-12), 7.04 (2H, d, J = 8.5 Hz, H-8), 
6.83 (2H, d, J = 8.5 Hz, H-13), 6.74 (2H, d, J = 8.5 Hz, H-9), 6.24 (1H, dt, J = 9.6, 1.0 Hz, H-4), 
5.70 (1H, dt, J = 9.6, 7.6 Hz, H-3), 3.80 (3H, s, OMe), 3.69 (2H, s, H-1), 3.23 (2H, d, J = 7.6 Hz,  
H-2), 2.93 (4H, m, H-5/6); δC (101 MHz, CDCl3): 158.8 (C-14), 154.3 (C-10), 132.4 (C-4), 132.2 
(C-7), 130.7 (C-11), 130.2 (C-12), 129.9 (C-8), 128.2 (C-3), 115.6 (C-9), 114.1 (C-13), 55.5 














The phenol 25 (100.0 mg, 0.26 mmol) was dissolved into DCM (4 mL) and the solution stirred 
under N2. The temperature was lowered to -78 °C using a liquid N2/ acetone bath and m-CPBA 
(75.0 mg, 77% in H2O, 0.34 mmol) was added to the reaction mixture. The reaction was allowed 
to proceed for 2 hours below -60 °C, producing a more polar product spot upon TLC monitoring 
(EtOAc: Hexane = 80:20). Saturated aqueous Na2CO3 (5 mL) was added at -60 °C and the 
reaction allowed to warm up to room temperature. The residue was extracted into DCM (10 mL 
x 3), the combined fractions were washed with brine (2 x 10 mL) and dried over MgSO4. A 
number of minor products were observed to form during the work-up. The product was purified 
by column chromatography (EtOAc: Hexane = 75:25) to result in a yellow oil 26 as a 4:3 mixture 
of Z/E isomers, (70.0 mg, 68 %): 
(E/Z) mixture: TLC Rf = 0.3 (EtOAc: Hexane = 80:20); IR vmax/cm-1 (CHCl3): 3152 (ArOH), 1325 
(S=O), 663 (C-S); HRMS (ES) m/z: 393.0646 [M- H+], C19H21O3S3 requires 393.0653. 
E-isomer: δH (400 MHz, CDCl3): 7.19 (2H, d, J = 8.7 Hz, H-12), 6.99 (2H, d, J = 8.7 Hz, H-8), 
6.89 (2H, d, J = 8.7 Hz, H-13), 6.75 (2H, d, J = 8.7 Hz, H-9), 6.28 (1H, dt, J = 14.6, 0.9 Hz, H-4), 
5.86 (1H, dt, J = 14.6, 7.2 Hz, H-3), 3.94 (2H, d, J = 1.2 Hz, H-1), 3.79 (3H, s, OMe), 3.45 (1H, 
ddd, J = 13.2, 7.2, 0.9 Hz, H-2a), 3.32 (1H, ddd, J = 13.2, 7.2, 0.9 Hz, H-2b), 2.90 (4H, m, H-5/6); 
δC (101 MHz, CDCl3): 160.0 (C-14), 155.2 (C-10), 135.1 (C-4), 131.4 (C-12), 131.0 (C-7), 129.8 
(C-8), 121.3 (C-11), 116.3 (C-3), 115.8 (C-9), 114.7 (C-13), 56.3 (C-1), 55.4 (OMe), 52.9 (C-2), 
40.3 (C-6), 34.8 (C-5). 
Z-isomer: δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.7 Hz, H-12), 6.98 (2H, d, J = 8.7 Hz, H-8), 
6.89 (2H, d, J = 8.7 Hz, H-13), 6.75 (2H, d, J = 8.7 Hz, H-9), 6.56 (1H, dt, J = 9.4, 1.0 Hz, H-4), 
5.75 (1H, dt, J = 9.4, 7.3 Hz, H-3), 3.96 (2H, s, H-1), 3.79 (3H,s, OMe), 3.56 (1H, ddd, J = 13.2, 
7.3, 1.0 Hz, H-2a), 3.48 (1H,ddd, J = 13.2, 7.3, 1.0  Hz, H-2b), 2.90 (4H, m, H-5/6); δC (101 MHz, 
CDCl3): 160.0 (C-14), 155.2 (C-10), 139.0 (C-4), 131.4 (C-12), 131.0 (C-7), 129.7 (C-8), 121.4 















The oxide 26 (200.0 mg, 0.51 mmol) was dissolved into DCM (5 mL) under N2, NEt3 (103.0 mg, 
1.02 mmol) was added to the solution, followed by DMAP (6.0 mg, 0.05 mmol). The temperature 
was lowered to -20 °C and acetyl chloride (52.0 mg, 0.66 mmol) was added slowly to the rapidly 
stirring solution and  the reaction was allowed to stir for 20 minutes at this point TLC monitoring 
produced a less polar product spot (EtOAc: Hexane = 60:40). DCM (25 mL) was added and 
washed with 1M HCl (2 mL) to remove NEt3 and DMAP, followed by the NaHCO3 (5 mL) to 
neutralise the reaction mixture. The combined fractions were washed with brine (2 x 10 mL) and 
dried over MgSO4. The resulting residue after solvent removal was purified by column 
chromatography (EtOAc: Hexane = 60:40) to afford a yellow solid 27 as a 3:4 mixture of Z/E 
isomers (196.0 mg, 88%) 
(E/Z) mixture: TLC Rf = 0.4 (EtOAc: Hexane =60:40); Mp (Hexane): 45- 47 °C; IR vmax/cm-1 
(CHCl3): 1700 (C=O), 1325 (S=O), 663 (C-S); HRMS (ES) m/z: 437.0910 [M+ H]+, C21H25O4S3 
requires 437.0915 
E-isomer: δH (400 MHz, CDCl3): 7.20 (4H, m, H-8/12), 7.01 (2H, d, J = 8.8 Hz, H-9), 6.90 (2H, 
d, J = 8.8 Hz, H-13), 6.34 (1H, dt, J = 14.8, 1.0 Hz, H-4), 5.93 (1H, dt, J = 14.8, 7.4 Hz, H-3), 
3.91 (2H, s, H-1), 3.80 (3H, s, OMe), 3.43 (1H, ddd, J = 12.0, 7.4, 1.0 Hz, H-2a), 3.29 (1H, ddd, 
J = 12.0, 7.4, 1.0 Hz, H-2b), 2.97 (4H, s, H-5/6), 2.28 (3H, s, H-2’); δC (101 MHz, CDCl3): 169.6 
(C-1’), 160.0 (C-14), 149.5 (C-10),137.3 (C-7), 134.3 (C-4), 131.3 (C-12), 129.7 (C-8), 121.9 (C-
9), 121.7 (C-11), 117.4 (C-3), 114.7 (C-13), 56.6 (C-1), 55.5 (OMe), 53.0 (C-2), 39.5 (C-6), 35.0 
(C-5), 21.2 (C-2’).   
Z-isomer: δH (400 MHz, CDCl3): 7.20 (4H, m, H-8/12), 7.01 (2H, d, J = 8.8 Hz, H-9), 6.90 (2H, d, 
J = 8.8 Hz, H-13), 6.57 (1H, dt, J = 9.4, 1.2 Hz, H-4), 5.80 (1H, dt, J = 9.4, 7.3 Hz, H-3), 3.94 
(2H, s, H-1), 3.80 (3H, s, OMe), 3.54 (1H, ddd, J = 12.0, 7.3, 1.2 Hz, H-2a), 3.47 (1H, ddd, J = 
12.0, 7.3, 1.2 Hz, H-2b), 2.97 (4H, s, H-5/6), 2.28 (3H, s, H-2’); δC (101 MHz, CDCl3): 169.6 (C-
1’), 160.0 (C-14), 149.5 (C-10), 138.3 (C-4), 137.2 (C-7), 131.4 (C-12), 129.7 (C-8), 121.8 (C-9), 
121.7 (C-11), 118.8 (C-3), 114.7 (C-13), 57.1 (C-1), 55.5 (OMe), 49.7 (C-2), 40.4 (C-6), 35.1 (C-














The oxide 26 (200.0 mg, 0.51 mmol) was dissolved into THF (5 mL) under N2, and NaH (26.5 
mg, 60% suspension in mineral oil, 0.66 mmol) added to the solution at -20 °C. The reaction 
was stirred for 15 minutes followed by the addition of methyl bromoacetate (109.0 mg, 0.714 
mmol). The reaction was then allowed to warm up to room temperature over 45 minutes with 
TLC monitoring indicating the completion of the reaction by conversion of starting material to a 
less polar product spot (EtOAc: Hexane = 60:40). NH4Cl (4 mL) was added to quench the 
reaction and the product was extracted into EtOAc (3 x 15 mL), which was dried over MgSO4. 
The resulting product was purified by column chromatography (EtOAc: Hexane = 55:45) to 
afford 28 as a clear oil as a 1:1 mixture of Z/E isomers (195.0 mg, 85%): 
(E/Z) mixture: TLC Rf = 0.4 (EtOAc: Hexane = 60:40); IR vmax/cm-1 (CHCl3): 1700 (C=O), 1325 
(S=O), 663 (C-S); HRMS (ES) m/z: 467.1004 [M+ H]+, C22H27O5S3 requires 467.1021 
E-isomer: δH (400 MHz, CDCl3):7.19 (2H, d, J = 8.7 Hz, H-12), 7.11 (2H, d, J = 8.7 Hz, H-8), 
6.89 (2H, d, J = 8.7 Hz, H-13), 6.83 (2H, d, J = 8.7 Hz, H-9), 6.34 (1H, dt, J = 14.6, 1.2 Hz, H-4), 
5.93 (1H, dt, J = 14.6, 7.4 Hz, H-3), 4.60 (2H, s, H-1’), 3.91 (2H, s, H-1), 3.80 (3H, s, H-1”), 3.79 
(3H, s, OMe), 3.43 (1H, ddd, J = 12.0, 7.4, 1.2 Hz, H-2a), 3.30 (1H, ddd, J = 12.0, 7.4, 1.2  Hz, 
H-2b), 2.93 (4H, s, H-5/6); δC (101 MHz, CDCl3): 169.5 (C-2’), 160.0 (C-14), 156.7 (C-10), 134.4 
(C-4), 133.1 (C-7), 131.3 (C-12), 129.8 (C-8), 121.8 (C-11), 117.2 (C-3), 115.0 (C-9), 114.7 (C-
13), 65.6 (C-1’), 56.5 (C-1), 55.4 (OMe), 53.0 (C-2), 52.3 (C-1’’), 39.8 (C-6), 34.8 (C-5).   
Z-isomer: δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.7 Hz, H-12), 7.09 (2H, d, J = 8.7 Hz, H-8), 
6.89 (2H, d, J = 8.7 Hz, H-13), 6.83 (2H, d, J = 8.7 Hz, H-9), 6.57 (1H, dt, J = 9.4, 1.2 Hz, H-4), 
5.79 (1H, dt, J = 9.4, 7.2 Hz, H-3), 4.61 (2H, s, H-1’), 3.94 (2H, s, H-1), 3.80 (3H, s, H-1”), 3.79 
(3H, s, OMe), 3.53 (1H, ddd, J = 12.0, 7.2, 1.2 Hz, H-2a) 3.47 (1H, ddd, J = 12.0, 7.2, 1.2 Hz, H-
2b), 2.93 (4H, s, H-5/6); δC (101 MHz, CDCl3): 169.5 (C-2’), 160.0 (C-14), 156.7 (C-10), 138.4 
(C-4), 133.0 (C-7), 131.4 (C-12), 129.8 (C-8), 121.7 (C-11), 118.7 (C-3), 115.0 (C-9), 114.6 (C-
















The oxide 26 (400.0 mg, 1.02 mmol) was dissolved in acetonitrile (8 mL) under N2, and K2CO3 
(282.0 mg, 2.04 mmol) and 2-iodoacetamide (377.0 mg, 2.04 mmol) were added to the solution 
at room temperature. The reaction was heated at 45°C and carefully monitored by TLC (EtOAc 
= 100%), which revealed the formation of a more polar spot corresponding to the amide product 
after 12 hours. Allowing the reaction to progress a further 12 hours in an attempt to consume all 
of the starting material did not show full conversion, so at this point the reaction was quenched 
with NaHCO3 (4 mL) and the product extracted into EtOAc (15 mL x 3), which was dried over 
MgSO4, and the solvent removed under vacuum. The residue was purified by column 
chromatography (MeOH: EtOAc= 5:95) to afford the amide product 29 as a 3:1 mixture of Z/E 
isomers as a colourless solid that was crystallized from methanol, (210.0 mg, 45%): 
(E/Z) mixture: TLC Rf = 0.3 (EtOAc = 100%); Mp (methanol): 86-88 °C; IR vmax/cm-1 (CHCl3): 
3524 and 3401 (NH2), 1688 (C=O), 1325 (S=O), 663 (C-S); HRMS (ES) m/z: 452.1026 [M+ H] +, 
C21H26NO4S3 requires 452.1024. 
E-isomer: δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.6 Hz, H-12), 7.13 (2H, d, J = 8.6 Hz, H-8), 
6.90 (2H, d, J = 8.6 Hz, H-13), 6.85 (2H, d, J = 8.6 Hz, H-9), 6.53 (1H, brs, NH), 6.34 (1H, dt, J = 
14.6, 1.2 Hz, H-4), 5.93 (1H, dt, J = 14.6, 7.4 Hz, H-3), 5.72 (1H, brs, NH), 4.47 (2H, s, H-2’), 
3.91 (2H, s, H-1), 3.81 (3H, s, OMe), 3.43 (1H, ddd, J = 12.0, 7.4, 1.2 Hz, H-2a), 3.30 (1H, ddd, 
J = 12.0, 7.4, 1.2  Hz, H-2b), 2.93 (4H, s, H-5/6); δC (101 MHz, CDCl3): 171.0 (C-2’), 160.0 (C-
14), 156.1 (C-10), 134.4 (C-4), 133.4 (C-7), 131.3 (C-12), 130.1 (C-8), 121.8 (C-11), 117.3 (C-
3),115.0 (C-13), 114.7 (C-9), 67.5 (C-1’), 56.6 (C-1), 55.5 (OMe), 53.0 (C-2), 39.7 (C-6), 34.7 
(C-5). 
Z-isomer: δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.6 Hz, H-12), 7.13 (2H, d, J = 8.6 Hz, H-8), 
6.90 (2H, d, J = 8.6 Hz, H-13), 6.85 (2H, d, J = 8.6 Hz, H-9), 6.57 (1H, dt, J = 9.4, 1.2 Hz, H-4), 
6.53 (1H, brs, NH), 5.79 (1H, dt, J = 9.4, 7.2 Hz, H-3), 5.72 (1H, brs, NH), 4.47 (2H, s, H-2’), 
3.94 (2H, s, H-1), 3.80 (3H, s, OMe), 3.53 (1H, ddd, J = 12.0, 7.2, 1.2 Hz, H-2a) 3.47 (1H, ddd, J 
= 12.0, 7.2, 1.2 Hz, H-2b), 2.93 (4H, s, H-5/6); δC (101 MHz, CDCl3): 171.0 (C-2’), 160.0 (C-14), 












114.0 (C-13), 114.7 (C-9), 67.5 (C-1’), 57.1 (C-1), 55.5 (OMe), 49.7 (C-2), 40.6 (C-6), 34.7 (C-
5).    
 
7.2 Biological Experimental 
 
7.2.1 General 
The cells used were A375 human malignant melanoma epithelial cell-line and WHCO1 
oesophogeal epithelial cell-line.  
 All cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) that contained 10% heat-
inactivated fetal bovine serum (FBS), 100 g/ml penicillin and 100 g/ml streptomycin that 
prevented contamination. All media, buffers and reagents were pre-incubated (unless otherwise 
stated) to 37 oC in a thermostat-controlled water bath.  
The cells were cultured in 100 mm petri dishes and allowed to reach between 80-95 % 
confluence prior to being split. The splitting procedure that was done under a sterile hood 
involved removal of the growth media and a quick wash to remove excess media with 
phosphate buffer (PBS) (3-4 mL) at pH 7.4, followed directly by incubating the cells in 0.05% 
tripsen-EDTA (2 mL) for 2-3 minutes at 37°C. The trypsin was used to detach the cells from the 
surface of the dish, and it was then deactivated with the growth media (3 mL). The cells were 
then pelleted by centrifugation for 4 minutes at 40000 rpm using a Hettich EBA 20 centrifuge. 
The pellet was then resuspended into growth media (1 mL) and using and using 10% of the 
cells to propagate further. 
7.2.2 Cell proliferation analysis  
The anti-proliferation effects of the analogues on tumour cells was measured by the MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation kit (Roche, Mannheim, 
Germany). The MTT reagent is a yellow tetrazolium salt that is reduced by viable cells to form 
purple formazan crystals, which can easily be quantified by spectroscopy. The amount of the 
formazan formed is directly related to the number of metabolically active cells. Each experiment 













The cells were plated in 135 l of media in the cell density of 2500 cells/ well for both the A375 
and WHCO1 cells. After plating, the cells were allowed to settle and grow in an incubator 
overnight at 37°C.  
On day 2, a stock dilution series (see Table 5), ranging from 100 mM to 0 of drug prepared in 
high DMSO. Each dilution was further diluted 100 fold into media, after which 10 l of the newly 
formed dilution was added to the cells (see Table 6), which gave a final drug concentration of 1 
in 1000 of the original solutions and a 0.1% DMSO. The cells were then incubated with the 
drugs at 37°C, 5% CO2 for 48 hours. 
On day 4, 10 l of the MTT reagent was added to each well and the cells incubated for a further 
4 hours at 37°C and followed by the addition of solubilisation reagent (10% SLS on 0.01 M HCl) 
(100 µl) and lastly incubated overnight at 37°C. 
Table 5: Dilution of drug stock (mM) 
1 2 3 4 5 6 7 8 9 10 11 
100 50 25 12.5 6.25 3.125 1.56 0.78 0.39 0.195 0 
Table 6: Final drug concentration in each well (µM) 
1 2 3 4 5 6 7 8 9 10 11 
100 50 25 12.5 6.25 3.125 1.56 0.78 0.39 0.195 0 
 
 
On day 5, the plates were read on a plate reader (EL800, Biotek Instruments, Winsooki, USA) at 
595nm and the background absorbance of the media, drugs and MTT (without cells) was also 
recorded at 595 nm. The background absorbance (with media only) was then subtracted from 
each reading and the data was analysed using Graphpad Prism 4, using a non-linear regression 
analysis fitted to sigmoidal dose-response curve with A595nm- baseline vs Log C to obtain the 
IC50 at 95% confidence interval. 
7.2.3 Animal Study 
A375 cells were grown to 80% confluence, harvested and then suspended in PBS at 2.5 x 107 
cells/ml. 100 µl of the suspension (2.50 x 106) was subsequently injected into the right hind 
posterior of each nude mice. At this point the mice were divided into two groups of 10 namely: 
the treatment group and the control group, and the treatment group each received the PMB-












drug doses were prepared by dissolving the test drug in 2.5% chondroitin, 10% DMSO and 
PEG400 to make up a solubilised solution and then administered to the mice intraperitoneally 
from day 1 until 21.  
The treated mice were monitored for signs of discomfort following the administration of the test 
drug and as such their health, weight and tumour size (measured by calipers) carefully 
recorded. Upon completion of the study at day 21, the mice were sacrificed by halothane and 
weighed and tumours were carefully removed and their volumes determined by (lenght2 x 
height)/2.53   
Stock solutions for all experiments were made as follows: 
PBS 10 X solution: 
1.37M NaCl 
27 mM KCl 
43 mM Na2HPO4.2H2O (pH 7.4) 
14 mM KH2PO4 
PBS 1 X solution:  
1 part “PBS 10X” in 9 parts distilled H2O – 
mixed, autoclaved and stored at 4 oC. 
 
SLS – Solubilisation:  
10% SLS in 0.01M HCl 
The MTT solution: 
100mg of MTT in 20 ml PBS buffer. Stored in 
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